Taking the Stage: Scientific Conferences

May 29, 2026

Rapid Oral Abstract Session

1:12-1:18 PM CDT

7011 - Golcadomide (GOLCA), a potential, first‑in‑class, oral CELMoD + Pola‑RCHP in patients (pts) with newly diagnosed aggressive B‑cell lymphoma (a‑BCL): Safety and 12‑month (mo) efficacy results.

Marc S. Hoffmann, Grzegorz S. Nowakowski, Michal Kwiatek, Maria Bouzani, Dagmara Zimowska-Curylo, Muhamad Alhaj Moustafa, Alejandro Martin Garcia-Sancho, Juan-Manuel Sancho, Wojciech Jurczak, Arpankumar Patel, Floriane Boucaud, Argyrios Gkasiamis, Mark Kaplan, Arnaud Amzallag, Matt Stokes, Tanvi Jindja, Serena K. Perna, Theodoros Vassilakopoulos

---------------------------------------------------------------------- 

Oral Abstract Session

2:45–2:57 PM CDT

4500 - A phase 2 randomized trial of radium‑223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).

Rana R. McKay, Pamela J. Atherton, Karla V. Ballman, Heather Jacene, Ronald C. Chen, Atish D. Choudhury, Joshua M. Lang, Suzanne Cole, Tarek Al Baghdadi, Young Kwok, Alan Tan, Stephanie A. Berg, Himisha Beltran, Michael J. Morris, Bradley A. McGregor, Tian Zhang, Matthew D. Galsky, Jonathan E. Rosenberg, Daniel J. George, Toni K. Choueiri

---------------------------------------------------------------------- 

Oral Abstract Session

3:57-4:09 PM CDT

4513 - Health‑related quality of life (HRQOL) with pembrolizumab or observation for high‑risk muscle‑invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501).

Ronald C. Chen, Elizabeth R. Plimack, Mary K. Gajewski, Matthew I. Milowsky, Jonathan E. Rosenberg, Daniel J. George, Tian Zhang, Arjun V. Balar, Petros Grivas, Srikala S. Sridhar, Scott Tykodi, Ulka N. Vaishampayan, Andrea B. Apolo, Gary H. Lyman

---------------------------------------------------------------------- 

3:45-3:57 PM CDT

7503 - DREAMM‑9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant‑ineligible (TI) newly diagnosed multiple myeloma (NDMM).

Saad Z. Usmani, Michal Mielnik, Aránzazu Alonso, Al-Ola A. Abdallah, Mamta Garg, Wojciech Janowski, Youngil Koh, Enrique M. Ocio, Hang Quach, Karthik Ramasamy, Alberto Oriol Rocaguera, Paula Rodríguez-Otero, Irwindeep Sandhu, Katja C. Weisel, Chris Brawley, Miguel Murillo, Farrah Pompilus, Jacqueline L. Egger, Morrys C. Kaisermann, Marek Hus

---------------------------------------------------------------------- 

Rapid Oral Abstract Session

2:57-3:03 PM CDT

9005 - Support of academic non‑clinical efforts for cancer investigator faculty at Association of American Cancer Institutes.

Paula M. Fracasso, Thomas J. George, Hailey Honeycutt, Nicole L. Simone, Julie A. Sosa, Carrie B. Lee, Jenna Hoopes, Christopher Lieu, Stephanie J. Si Lim, Quan P. Ly, Julie Vose, Theresa L. Werner, Julia R. White, Lee G. Wilke, Kate Shaw, Kendra Cameron, Karen L. Reckamp

---------------------------------------------------------------------- 

May 30, 2026

Poster Session

1:30–4:30 PM CDT

12136 - The role of pretreatment vitamin D insufficiency in racial disparity in taxane‑induced peripheral neuropathy: Results from the SWOG S0221 trial.

Nam Nguyen‑Hoang, Ciao‑Sin Chen, Gary Zirpoli, George T. Budd, Lajos Pusztai, Gabriel N. Hortobagyi, Kathy S. Albain, Andrew K. Godwin, Alastair M. Thompson, Norah L. Henry, Christine B. Ambrosone, Kathleen A. Stringer, Daniel L. Hertz

---------------------------------------------------------------------- 

Poster Session

1:30–4:30 PM CDT

TPS12172 - A late‑phase randomized open‑label multi‑cohort trial to evaluate immune‑related adverse events with different standard‑of‑care dosing strategies of standard‑of‑care immunotherapies: ImmuRAD trial.

Anup Kasi, Anusha Chidharla, Raed M. Al‑Rajabi, Shannon Bradbury, Milind A. Phadnis, Lauren Clark, Chao H. Huang, Gary C. Doolittle, Prakash C. Neupane, Nina S. Mathew, Elizabeth Wulff, Haoran Li, Saqib Abbasi, Joaquina C. Baranda, Weijing Sun, Rahul A. Parikh

---------------------------------------------------------------------- 

Oral Abstract Session

3:00–3:12 PM CDT

LBA2000 - Final results of a randomized, controlled, phase 3 trial comparing resection and post‑operative stereotactic radiation versus resection and cesium‑131 tile‑based radiation for treatment of newly diagnosed brain metastases.

Jeffrey S. Weinberg, Heather Y. Lin, Mary Frances McAleer, Jeffrey S. Wefel, Simon Hanft, Brandon S. Imber, Nelson S. Moss, Kimberly Hoang, Fen Wang, Imran Mohiuddin, Akshikumar Mistry, Nitesh Patel, Huong Pham, John Wanebo, Clark C. Chen, Alexandra Paul, Lindsey Sloan, Matthew Shepard, Vincent Dinapoli, Thomas H. Beckham

---------------------------------------------------------------------- 

Oral Abstract Session

4:12-4:24 PM CDT

5004 - A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone‑sensitive prostate cancer (A‑DREAM / Alliance A032101).

Atish D. Choudhury, Karla V. Ballman, Melissa A. Reimers, Andrew L. Laccetti, Fabrice Smieliauskas, Praful Ravi, Han Xiao, Katharine Dooley, David W. Hillman, Gina L. Mazza, Benjamin Gartrell, Preston D. Steen, Thomas J. Smith, Himisha Beltran, Ronald C. Chen, Stephanie A. Berg, Rana R. McKay, Matthew D. Galsky, Jonathan E. Rosenberg, Michael J. Morris

---------------------------------------------------------------------- 

Oral Abstract Session

4:24-4:36 PM CDT

5005 - Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT‑47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.

Alicia K. Morgans, Olivia Bobek, Daniel H. Kwon, Stephanie A. Berg, Deepak Kilari, Russell Z. Szmulewitz, Stuart H. Bloom, Elizabeth Wulff, Praful Ravi, Daniel A. Roberts, Karla V. Ballman, Emmanuel S. Antonarakis, Charles J. Ryan

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

4218 - Phase IIb randomized trial of FOLFIRINOX plus ibrilatazar (ABTL0812) versus placebo as first‑line treatment in metastatic pancreatic cancer: An analysis from the PanC‑ASAP study.

Davendra Sohal, Anup Kasi, Inmaculada Gallego, Adelaida Garcia‑Velasco, Alberto Carmona, Alberto Rodrigo, Susana Roselló, François Ginghinelli, Laura Layos, Emmanuel Mitry, Maria Passhak, Andrés J. Muñoz Martín, Bartomeu Massuti, Oriol Pedrós‑Gámez, Maria Navarro Jiménez, Héctor Pérez‑Montoyo, Carles Domenech, Antoine Hollebecque, Talia Golan, Teresa Macarulla

---------------------------------------------------------------------- 

Poster Session 9:00–12:00 PM CDT

4205 - Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin‑positive advanced pancreatic adenocarcinoma.

Carlos Diego H. Lopes, Anup Kasi, Laith I. Abushahin, Dana B. Cardin, Heinz-Josef Lenz, Farshid Dayyani, Wells A. Messersmith, Nkiruka Ezenwajaku, Paul E. Oberstein, Ravi K. Paluri, Reema A. Patel, Kathleen L. Pfaff, Edward Kim, Aparna Kalyan, Brandon G. Smaglo, Manik A. Amin, Mohammed N. Al Hallak, Olumide B. Gbolahan, Helen X. Chen, Anna Spreafico

---------------------------------------------------------------------- 

Oral Presentation

3:00-6:00PM CDT

A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101).

Choudhury AD, Ballman K, Reimers MA, Laccetti A, Smieliauskas F, Ravi P, Xiao H, Dooley K, Hillman D, Mazza GL, Gartrell B, Steen P, Smith TJ, Beltran H, Chen RC, Berg S, McKay RR, Galsky MD, Rosenberg JE, Morris M.

---------------------------------------------------------------------- 

May 31, 2026

Poster Session

9:00-12:00 PM CDT

4559 - Association of baseline quality of life (QOL) and early death in patients with metastatic renal cell carcinoma (mRCC) in the real-world prospective observational ODYSSEY study.

Michael R. Harrison, Elizabeth Wulff, Yasser Ged, Benjamin L. Maughan, Nrupen A. Bhavsar, Leonard J. Appleman, Yousef Zakharia, Brian A. Costello, Deepak Kilari, Sorab Gupta, Melyssa Bratton, Paul Monk III, Ulka N. Vaishampayan, Tracy L. Rose, Sarah Jabusch, Kimberly T. Ward, Yuan Wu, Courtney Page, Tian Zhang, Daniel J. George, ODYSSEY Study Group

---------------------------------------------------------------------- 

Poster Session

9:00-12:00 PM CDT

TPS4641 - A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti–PD-(L)1–resistant advanced urothelial cancer: ECOG-ACRIN EA8231.

Monika Joshi, Se E. Kim, Petros Grivas, Elizabeth Wulff, Alicia K. Morgans, Kriti Mittal, Joshua Warrick, Melissa A. Reimers, Noah M. Hahn, Naomi B. Haas, Lynne I Wagner, Michael Carducci

---------------------------------------------------------------------- 

Rapid Oral Abstract Session

8:06-8:12 AM CDT

12010 - Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.

Jennifer A. Ligibel, Dawn L. Hershman, Amylou C. Dueck, Linda M. McCall, Brenda F. Ginos, Pamela J. Goodwin, Anna Weiss, Olwen Hahn, Patricia Spears, Electra D. Paskett, Judith O. Hopkins, Erica L. Mayer, Elizabeth S. Frank, Vanessa Bernstein, Vered Stearns, Julia R. White, Thomas Waden, Eric P. Winer, Lisa A. Carey, Ann H. Partridge

---------------------------------------------------------------------- 

Poster Session

9:00-12:00PM CDT

5078 - Transient prostate-specific antigen flare induced by lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration resistant prostate cancer.

Cheng T, Binz K, Bullangi S, Wulff E, Abbasi S, Donald J, Yap WY, Shen X, Chen RC, Parikh RA, Li H.

Rapid Oral Abstract Session

4:30–4:36PM CDT

LBA5012 - Early results of COMPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.

Nancy P. Mendenhall, Curtis Bryant, Aaron J. Katz, Christopher G. Morris, Amy M. Crisp, Todd A. DeWees, Folakemi Odedina, Jeff M. Michalski, Jerry D. Slater, Seungtaek Choi, Hesham Gayar, Christopher Sinesi, Robert A. Zlotecki, David T. Marshall, Mark R. Waddle, Bradford Hoppe, Timothy Showalter, Steven J. DiBiase, William R. Lee, Ronald C. Chen

---------------------------------------------------------------------- 

9:00–12:00 PM CDT

5078 - Transient prostate‑specific antigen flare induced by lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration resistant prostate cancer.

Tiewei Cheng, Rana R. McKay, Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez‑Veiga, Ruslan Croitoru, Matko Kalac, Yiyun Tang, Arnulf Stenzl

---------------------------------------------------------------------- 

9:00–12:00 PM CDT

5092 - Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone‑sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.

Arnulf Stenzl, Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Ruslan Croitoru, Mingming Lian, Zhiqiang Xiao, Janet Kim, Matko Kalac, Yiyun Tang, Arun Azad

---------------------------------------------------------------------- 

9:00–12:00 PM CDT

5093 - Predictors of treatment (tx) duration in patients (pts) with metastatic hormone‑sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA): A post hoc analysis of ARCHES.

Andrew J. Armstrong, Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez‑Veiga, Alexis Serikoff, Ruslan Coritrou, Matt Rosales, Matko Kalac, Yiyun Tang, Arnulf Stenzl, Arun Azad

---------------------------------------------------------------------- 

9:00–12:00 PM CDT

5023 - Image‑only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies.

Xinglei Shen, Rana R. McKay, Yi Ren, Xiaoxuan Yang, Wouter Zwerink, Chinmayi Pandya, Tiffany Way, Marcella Ku, Suzanna Lee, Anders Meyer, Janet E. Cowan, Imelda Tenggara, Chien-Kuang C. Ding, Katherine L. OShaughnessy, Huej-Chung Rebecca Huang, Rikiya Yamashita, Meghan Tierney, Andre Esteva, Erin L. Stewart, Peter Carroll

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

5040 - Quality of life analysis from a multicenter, randomized, phase 2, investigator‑initiated ETCTN trial of olaparib + radium‑223 versus radium‑223 in metastatic castration‑resistant prostate cancer with bone metastases (COMRADE).

Rana R. McKay, Wanling Xie, Archana Ajmera, Arlene Areneta, Edmund Folefac, Arif Hussain, Christos Kyriakopoulos, Adam C. Olson, Rahul A. Parikh, Salma K. Jabbour, Geoffrey I. Shapiro

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

8088 - Analysis of corticosteroid exposure on efficacy of tarlatamab in small cell lung cancer: A multicenter retrospective study.

Ty M. Moore, Courtney C. Cavalieri, Sabrina Cannon, Jessica Campaign Mauser, Emma Jones, Amanda Cass, Alexander Olinger, Bryce Bortka, Allison Schepers, Jacob Hobbs, Lauren Blackwell, Kori Holman, Sarah Blocker, Diana Kim, Chao H. Huang, Prakash C. Neupane, Sanjana Mullangi, Manidhar R. Lekkala, Haoran Li, Timothy J. Schieber

---------------------------------------------------------------------- 

Poster Session

9:00-12:00 PM CDT

Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.

Helena A. Yu, Jyoti D. Patel, Nisha A. Mohindra, Susan C Scott, Julia K. Rotow, Christina S. Baik, Danny Nguyen, Alex Spira, Sarah W. Gorden, Haobin Chen, James Stevenson, Manmeet S. Ahluwalia, Minal A Barve, Shetal A. Patel, David Berz, Chao H. Huang, Sergey Yurasov, Julio Hajdenberg, Shannon Matheny, Melissa L. Johnson.

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

9534 - Optimal timing of circulating tumor DNA (ctDNA) dynamics to prognosticate immune checkpoint inhibitors (ICI) efficacy in patients with advanced stage melanoma.

Vincent T. Ma, Amir W. Forati, Alice Y. Zhou, Trevor McCracken, Meena Hosny, Alyssa K. Steinle, Golbarg Rahimi, Jahmesh D. Patel, Caroline Burkey, Jessica Caraway, Andrew Wood, Madison S. Harris, Alexander Birbrair, Deepak M. Sahasrabudhe, Fauzia Hollnagel, Gary C. Doolittle, Nina S. Mathew, Gino K. In, Adrienne I. Victor

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

9533 - Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma.

Alyssa K. Steinle, Vincent T. Ma, Amir W. Forati, Alice Y. Zhou, Trevor McCracken, Meena Hosny, Golbarg Rahimi, Jahmesh D. Patel, Caroline Burkey, Jessica Caraway, Andrew Wood, Madison S. Harris, Alexander Birbrair, Deepak M. Sahasrabudhe, Fauzia Hollnagel, Gary C. Doolittle, Nina S. Mathew

---------------------------------------------------------------------- 

June 1, 2026

Rapid Oral Abstract Session

8:00-8:06 AM CDT

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).

Shilpa Gupta, Karla V. Ballman, Andrea B. Apolo, Srikala S. Sridhar, Ronald C. Chen, Timothy A. Chan, Yujia Wen, Stephanie Berg, Aihua E. Yen, Shiva Baghaie, Parminder Singh, Melissa A Reimers, Michael J. Morris, Matthew D. Galsky, Jonathan E. Rosenberg.

---------------------------------------------------------------------- 

Poster Session

9:00-12:00 PM CDT

6576 - Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types.

Ruben A. Mesa, Lucia Masarova, Brandi Reeves, Zhijian Xiao, Albert Qin, Harinder Gill, Jie Jin, Norio Komatsu, Keita Kirito, Firas El Chaer, Lynda M. Foltz, Tsewang Tashi, Ghaith F. Abu Zinah, Lee-Yung Shih, Dawn Maze, Stephen Oh, Oleh Zagritjtschuk, Toshiaki Sato, Abdulraheem Yacoub, John Mascarenhas

---------------------------------------------------------------------- 

Clinical Science Symposium

10:09-10:21 AM CDT

External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814.

Corey W. Speers, Alexander Piehler, Allison Meisner, Jingbin Zhang, William E. Barlow, Wouter Zwerink, Lajos Pusztai, Priyanka Sharma, Calvin Y. Chao, Alastair M. Thompson, Andrew K. Godwin, Kathy S. Albain, Jacqueline R. Griffin, James M. Rraie

Poster Session

1:30-4:30 PM CDT

(RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US.

Vk Gadi, Lowell L Hart, Paolo Tarantino, Priyanka Sharma, Sarah L. Sammons, Panagiotis Mavros, Maneet Kaur, Nada Boualam, Catherine Keane, Gary M. Sopher, Purnima Pathak, Hope S. Rugo

---------------------------------------------------------------------- 

1:30–4:30 PM CDT

TPS650 - A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0‑1, HR+/HER2– breast cancer and Oncotype recurrence score ≤25 (OFSET): NRG‑BR009.

Eleftherios P. Mamounas, Gong Tang, Shannon L. Puhalla, Sandra M. Swain, Patricia A. Ganz, Norah L. Henry, Reena S. Cecchini, Sonya A. Reid, Priya Rastogi, Charles E. Geyer Jr., Julia R. White, Amy S. Clark, Tufia C. Haddad, Gregory A. Vidal, Norman Wolmark

---------------------------------------------------------------------- 

1:30–4:30 PM CDT

561 - Association of the 70‑gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.

Steven J. Isakoff, VK Gadi, Massimo Cristofanilli, Erin F. Cobain, Cathy L. Graham, Kent F. Hoskins, Priyanka Sharma, Laura A. Lee, Eduardo Dias, Linsey P. Gold, Eric A. Brown, Richard E. Fine, Cristina Lopez‑Penalver, Josien Haan, Nicole Stivers, Raquel Weber, Andrea Menicucci, William Audeh, Joyce O’Shaughnessy

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

7060 - Diagnostic accuracy of circulating tumor DNA for post‑remission surveillance in diffuse large B‑cell lymphoma: A systematic review and meta‑analysis.

Mohammad Ahsen Soomro, Mohamed Ahmed, Manzar Abbas, Hala Soomro, Nausheen Ahmed, Forat Lutfi, Joseph Bennett

---------------------------------------------------------------------- 

Poster Session

9:00–12:00 PM CDT

11068 - Prevalence and trends in rural patient enrollment in SWOG cancer clinical trials, 1992–2022.

Izumi Okado, Cathee Till, Raymond U. Osarogiagbon, Gary C. Doolittle, Dawn L. Hershman, Joseph M. Unger

April 19, 2026

Session PO.BCS01.01 - Application of Bioinformatics to Cancer Biology 1

2:00 PM - 5:00 PM

63 / 25 - Intratumoral Candida albicans associates with hypoxia and poor outcomes in non small cell lung cancer (NSCLC)

Chatterjee, D. J. Grencewicz, A. Loncar, J. Wu, R. Wu, A. Samouilov, S. Ferrandon, M. Kreamer, Y. Mehra, A. Carson, R. Hoyd, S. Jahanbakhshi, F. Choueiry, M. Anderson, M. Benej, D. Bosch, J. (. Zhu, T. Bocklage, M. McCarter, A. Tarhini, B. Salhia, C. A. Moskaluk, G. Riedlinger, S. Yao, A. Masood, S. Hardikar, M. N. Ilozumba, C. M. Ulrich, A. R. Naqash, C. H. Chan, C. D. Shriver, D. P. Mudaranthakam, A. Pallerla, M. Churchman, R. J. Rounbehler, L. Chambers, M. F. Kalady, N. C. Denko, D. P. Carbone, D. Spakowicz

----------------------------------------------------------------------

Session PO.CL01.22 - Circulating Tumor Cells, Metastasis, and Dissemination Biology 1

2:00 PM - 5:00 PM

1062 / 2 - Longitudinal monitoring of circulating tumor cells (CTC) reveals dynamic CTC behaviors associated with disease progression and survival in ALK-positive NSCLC

Chen, S. Fouladdel, L. Kidder, Y. Tang, H. Ball, H. Serhan, Z. Qin, A. Qin, A. Liu, X. Cheng, L. Bao, V. Kathawate, L. Goo, M. Horn, S. Fry, A. N. Hata, J. Gainor, J. J. Lin, S. Hinton, C. H. Huang, N. Merrill, A. M. Udager, P. J. Ulintz, S. Merajver, S. Nagrath

----------------------------------------------------------------------

Session PO.CL01.15 - Prognostic Biomarkers 1

2:00 PM - 5:00 PM

1196 / 20 - A pre-treatment cfDNA methylation signature linking prognosis and drug-resistance biology in pancreatic ductal adenocarcinoma

Manne, U. Manne, L. Yu, W. Yang, M. K. Niazi, R. Paluri, A. Kasi, P. Bajpai, A. Leyva

----------------------------------------------------------------------

Session PO.CL07.03 - Targeting DNA Repair, Cell Cycle, and Tumor Metabolism

2:00 PM - 5:00 PM

1262 / 7 - Depletion of dominant-negative mutant p53 improves the efficacy of mutant p53 reactivators

S. John, M. Bhosale, A. Parrales, A. Ranjan, T. Iwakuma

----------------------------------------------------------------------

Session PO.PR02.03 - Cancer in the Community: Epidemiology, Experimental Knowledge, Action, and Communication

2:00 PM - 5:00 PM

930 / 12 - Mediterranean versus Western diet - preventative and interventional effects of dietary lipids on colorectal tumor growth and biology

C. Wallingford, A. Mahanty, R. Hammontree, A. Magstadt, J. Davis

----------------------------------------------------------------------

Session PO.TB05.01 - Developmental Origins, Drivers, and Heterogeneity in Pediatric Cancer

2:00 PM - 5:00 PM

622 / 1 - Infant KMT2A::AFF1 acute lymphoblastic leukemia stem cell model reveals early impact on the proteome

Prosser-Dombrowski, I. Pushel, P. P. Kumar, T. Gremminger, M. Rekowski, M. S. Farooqi, M. Washburn, J. L. Vivian, J. M. Perry

----------------------------------------------------------------------

Session LBPO.CH01 - Late-Breaking Research: Chemistry

2:00 PM - 5:00 PM

042 / 22 - Elucidating plasma bacterial and host derived metabolites unique to epithelial ovarian cancer

E. Mahoney, I. Medina-Meza

----------------------------------------------------------------------

Session PO.ET02.07 - Innovative Therapeutic Modalities and Translational Platforms

2:00 PM - 5:00 PM

307 / 25 - Triple-negative breast cancer growth and metastasis suppression by CCN5 is mediated by Merlin/NF2 and Orai-1 molecular signatures

Haque, G. Maity, J. L. Porter, S. Banerjee, S. K. Banerjee

----------------------------------------------------------------------

Session PO.CL06.02 - Mechanistic Insights for Targeted Therapies in Pediatric Cancer

2:00 PM - 5:00 PM

1169 / 22 - Global proteomic analysis of pediatric T-cell acute lymphoblastic leukemia patient samples reveals distinct protein upregulation signature

I. Pushel, T. Gremminger, L. Lansdon, M. Rekowski, M. S. Farooqi, M. Washburn, K. August

April 20, 2026

Session PO.TB02.01 - In Vivo Imaging

9:00 AM - 12:00 PM

2132 / 4 - Near-Infrared Claudin-1 antibody enables accurate detection of primary and metastatic colorectal tumors in mice

Bravo, S. Liu, S. Amirfakhri, B. Eddins, K. Kobayashi, J. Zaker, R. Hoffman, S. Talib, A. M. Mohs, P. Dhawan, M. Bouvet

----------------------------------------------------------------------

Session PO.BCS02.02 - Large Language Models in the Clinic

2:00 PM - 5:00 PM

2743 / 7 - Deploying artificial intelligence driven digital pathology for real world clinical decision-making in pancreatic cancer

Manne, U. Manne, A. Leya, A. R. Akbar, A. Noonan, A. Kasi, A. Esnakula, R. Paluri, A. V. Parwani, M. K. Niazi

----------------------------------------------------------------------

Session LBPO.ET02 - Late-Breaking Research: Experimental and Molecular Therapeutics 2

2:00 PM - 5:00 PM

180 / 2 - Isocitrate dehydrogenase (IDH) isoform switch confers resistance to ivosidenib in myelodysplastic neoplasm

A. Yacoub, N. Lux, P. R. Gonzales, R. Balusu, S. Golem, S. D. Hyter, W. Cui

----------------------------------------------------------------------

Session PO.BCS01.15 - Sequence Analysis

9:00 AM - 12:00 PM

1510 / 17 - CASTLE: long-read sequencing panel of cancer cell lines to improve standards of somatic variant calling and benchmarking

M. Kolmogorov, A. G. Kesus, A. Bryant, T. Ahmad, B. Yoo, S. Aganezov, A. Goretsky, A. Donmez, L. Lansdon, J. Gardner, B. McNulty, S. Sacco, J. Shetty, Y. Zhao, B. Tran, G. Narzisi, A. Hellend, C. Bi, A. Walter, M. Gibson, I. Pushel, E. Guest, T. Pastinen, N. Robine, K. H. Miga, M. S. Farooqi, B. Paten

----------------------------------------------------------------------

Session PO.RSP01.01 - Regulatory Science and Policy

9:00 AM - 12:00 PM

1401 / 10 - A novel statistical framework for surrogate endpoint prediction of survival in neoadjuvant breast cancer trials

K.S. Santos-Parker, J. R. Santos-Parker, W. F. Symmans, L. J. Esserman, C. Yau, A. DeMichele, L. V. Veer, D. Yee, F. Reyal, H. Earl, J. Abraham, D. Cameron, P. Hall, J. Boughey, M. Goetz, G. Sonke, M. Martín, S. López-Tarruella, P. Sharma, R. Freiberg, R. Freiberg, J. Perlmutter, A. Bardia, M. Eklund, L. Pusztai

----------------------------------------------------------------------

Session PO.BCS01.09 - Integrative Computational Approaches 1

9:00 AM - 12:00 PM

1489 / 28 - STniche: An approach to identify functional niches in the tumor microenvironment from spatial transcriptomics

S. Arunachalam, O. Ospina, A. C. Soupir, X. Yu, B. L. Fridley

----------------------------------------------------------------------

Session PO.EN01.01 - Hormone Receptor Signaling and Therapeutic Targeting

9:00 AM - 12:00 PM

2284 / 6 - Progesterone receptor modulates the antigen processing and presentation machinery: Decreasing MHC class I expression on tumor

J. Tinoco, E. Chowanec, A. G. Heard, C. R. Hagan

----------------------------------------------------------------------

Session PO.CL05.05 - Immunomodulatory Effects of Targeted Therapies

9:00 AM - 12:00 PM

2577 / 21 - Free and encapsulated tunicamycin significantly enhances the suppression of PD-L1 by gemcitabine through blocking K-RasG12D expression in pancreatic ductal adenocarcinoma cells

H. Breier, S. P. Upadhyay, O. Ommi, S. Bossmann, S. Banerjee, S. K. Banerjee

----------------------------------------------------------------------

Session PO.CT01.05 - Phase II and Phase III Clinical Trials

2:00 PM - 5:00 PM

147 / 11 - High dose intravenous ascorbate with chemotherapy as NAC for muscle invasive cisplatin ineligible bladder cancer patients

B. Woolbright, J. Drisko, J. Taylor, Q. Chen, R. Parikh

----------------------------------------------------------------------

Session PO.TB03.05 - Migration and Invasion

2:00 PM - 5:00 PM

3464 / 3 - Defining the role of CRK and CRKL in glioblastoma invasiveness: from cell culture to mouse models

P. Hettiarachchi, N. Large, T. P. Park

----------------------------------------------------------------------

Session PO.ET05.02 - Cellular Responses to Anticancer Drugs

2:00 PM - 5:00 PM

2946 / 23 - RQ43: A quinoline derivative that inhibits pancreatic cancer cell EMT and migration

S. Das, Q. Chen

----------------------------------------------------------------------

Session PO.ET05.02 - Cellular Responses to Anticancer Drugs

2:00 PM - 5:00 PM

2941 / 18 - Pharmacologic ascorbate exerts anticancer activity through ROS-dependent metabolic vulnerability in MYCN-amplified neuroblastoma

T. Farah, Q. Chen

April 21, 2026

Session PO.MCB07.03 - Mechanisms and Dynamics of Gene Expression

2:00 PM - 5:00 PM

5958 / 13 - APOBEC4, a novel regulator of p53-dependent tumor suppression

D. Thapa, A. Ranjan, A. P. Briones, E. Thoenen, S. Nishikawa, J. Vivian, T. Iwakuma

----------------------------------------------------------------------

Session PO.BCS01.05 - Application of Bioinformatics to Cancer Biology 5

2:00 PM - 5:00 PM

5442 / 9 - Identifying cell-cell interactions across spatial scales in spatial transcriptomics

C. Soupir, M. T. Hayes, B. J. Manley, L. C. Peres, J. Wrobel, B. Fridley

----------------------------------------------------------------------

Session PO.MCB05.01 - Insights into Genomic Instability

9:00 AM - 12:00 PM

4694 / 14 - Oxidative base damage to telomeres sensitizes cancer cells to ATR inhibition

Garbouchian, N. C. Moreno, A. Dey, P. L. Opresko, R. Barnes

----------------------------------------------------------------------

Session PO.MCB09.06 - Metabolic Alterations in Colorectal and Gastrointestinal Cancers

9:00 AM - 12:00 PM

4711 / 9 - Investigating synergistic impact of diet-induced hyperinsulinemia and mutant Kras on colorectal cancer metastasis

A. Mahanty, C. Wallingford, A. Magstadt, R. Hammontree, J. Davis

----------------------------------------------------------------------

Session PO.MCB03.01 - RAS/MAPK Signaling, KRAS Targeting, and Adaptive Resistance

2:00 PM - 5:00 PM

5981 / 6 - Metabolic stress conditions dictate MAPKAPK2-dependent efficiency of MEK1/2 inhibition in colorectal carcinoma

B. Kumar, N. Kumari, X. Chen, A. M. Baldwin, K. I. Clemons, M. Alharakeh, L. Calisto, Q. Zhang, J. Min, B. Xiao, A. B. Singh, B. Wang, B. J. North

----------------------------------------------------------------------

Session PO.IM01.12 - Immunomodulatory Agents

9:00 AM - 12:00 PM

4323 / 27 - The SPHK2 inhibitor opaganib potentiates tumor-intrinsic STING activation in triple-negative breast cancer in vitro

C.R. Worcester, A. Mitra, H. B. Pathak, S. R. Stecklein

----------------------------------------------------------------------

Session LBPO.ET03 - Late-Breaking Research: Experimental and Molecular Therapeutics 3

2:00 PM - 5:00 PM

352 / 9 - First in class hSSB2 activator as a dual therapeutic strategy for overcoming RAS/MAPK inhibitor resistance while protecting normal epithelia in aggressive cancers

A.J. Norris, A. Ravisankar, E. M. Singer, J. Rodriguez, J. P. Whitelegge, M. Kumari, P. Bhanja, R. M. Chugh, S. Saha, W. H. McBride

----------------------------------------------------------------------

Session PO.TB10.08 - Spatial Niches and Functional Boundaries within the Tumor Microenvironment 1

9:00 AM - 12:00 PM

4966 / 23 - A single-cell spatial proteomic analysis of the TNBC microenvironment defines genotype-specific features

D. Pueschl, D. Bragen, J. Lin, A. Nayak, D. A. Oldridge, K. Bennett, V. Fang, K. Investigators, K. Offit, A. K. Godwin, P. A. James, P. L. Mai, S. H. Teo, A. Antoniou, G. Chenevix-Trench, E. J. Wherry, S. M. Domchek, K. L. Nathanson

----------------------------------------------------------------------

Session PO.MCB05.01 - Insights into Genomic Instability

9:00 AM - 12:00 PM

4683 / 3 - Loss of nuclear integrity at persistent DNA bridges ties PARP inhibitors to cGAS/STING signaling

E. Koçak, K. A. Larkin, N. R. Ader, Y. Hu, K. Li, C. P. Lusk, A. D. Staniszewska, M. R. Albertella, M. C. King

----------------------------------------------------------------------

Session PO.CL09.01 - Precision Oncology and Real World Data

9:00 AM - 12:00 PM

5348 / 16 - Tumor remodeling pathways are enriched in the tumor microenvironment of obesity-associated colorectal cancer

Fujiwara, S. Mukherjee, Y. Zhang, J. Wang, E. B. Toegel, T. B. Castria, B. Salhia, A. M. Noonan, M. J. Cavnar, D. W. Kim, M. Rehman, P. B. Boland, M. L. Fishel, C. H. Chan, M. M. Gage, H. Hatoum, J. White, R. J. Rounbehler, M. Churchman, D. Vadehra

----------------------------------------------------------------------

Session PO.CL05.09 - Inflammation, Immunity, and Cancer

2:00 PM - 5:00 PM

6589 / 22 - Nrf2 as a therapeutic target to improve T cell function in muscle invasive bladder cancer (MIBC)

Tripathi, N. Santana-Magal, J. Rack, D. Dasgupta, B. L. Woolbright, K. Pyaram

----------------------------------------------------------------------

Session PO.BCS01.12 - New Software Tools for Data Analysis

2:00 PM - 5:00 PM

5510 / 15 - Hunting for microsatellite instability in long-read data with Owl

Kronenberg, K. P. Chua, M. J. Chaisson, B. Yoo, L. Lansdon, W. J. Rowell, E. Dolzhenko, K. K. Huang, P. Tan, S. S. Bhise, E. Fan, M. Mendoza, E. O'donnell, T. Pastinen, E. R. Lawlor, S. N. Furlan, M. S. Farooqi, M. A. Eberle

----------------------------------------------------------------------

Session PO.CTP01.02 - Phase I and Phase II Clinical Trials in Progress

2:00 PM - 5:00 PM

269 / 3 - Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies

D. Akhavan, J. P. McGuirk, L. Wirthlin, N. Dudley, R. Balusu, R. Soder, S. J. Weir, S. Abhyankar, T. Bruns

----------------------------------------------------------------------

Session PO.CL05.09 - Inflammation, Immunity, and Cancer

2:00 PM - 5:00 PM

6594 / 27 - Establishing ex vivo models for targeting leukemic stem cells to investigate relapse and refractory pediatric leukemias

Kandel, J. M. Nemechek, T. Manor, J. N. Maina, J. M. Perry

----------------------------------------------------------------------

Session PO.ET08.01 - Strategies to Enhance the Therapeutic Index of Radiotherapy

9:00 AM - 12:00 PM

4628 / 5 - Mitochondrial serine/threonine phosphatase, phosphoglycerate mutase 5 (PGAM5) is a novel target to promote abdominal radiotherapy

H. Rehman, R. M. Chugh, P. Bhanja, S. Krepel, S. Saha

----------------------------------------------------------------------

Session PO.CL08.02 - Effects of Ionizing Radiation on Normal Tissues and FLASH Radiation Research

9:00 AM - 12:00 PM

5267 / 4 - Reprogramming of pyruvate metabolism overcomes sex-specific differences in intestinal stem cell radiosensitivity and improves the therapeutic ratio for abdominal irradiation

Krepel, P. Bhanja, R. M. Chugh, S. H. Rehman, S. Saha

----------------------------------------------------------------------

Session PO.CL08.01 - Radiation and Photodynamic Therapy Response Modifiers

2:00 PM - 5:00 PM

6622 / 23 - Novel selective binders for gastrointestinal DCLK1 isoforms

Uzmi, S. Umar, P. Karyala, R. V. Papineni

April 22, 2026

Session PO.TB06.01 - Biological Mechanisms of Tumor and Normal Tissue Response and Clinical Studies

9:00 AM - 12:00 PM

7369 / 6 - Hypofractionated prostate and pelvic nodal radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A retrospective analysis of oncologic outcomes and toxicity

E. Reddy, A. A. Ansari, I. Haque, D. Khaled, J. Park

----------------------------------------------------------------------

Session PO.BCS01.17 - Mathematical Modeling and Statistical Methods

9:00 AM - 12:00 PM

6844 / 15 - Functional data analysis of spatial protein imaging data using spatial trajectories with application to ovarian cancer

B.L. Fridley, A. C. Soupir, D. Liao, C. Sakitis, J. Schildkraut, A. B. Lawson, M. K. Townsend, S. Tworoger, K. L. Terry, J. Wrobel, L. C. Peres

----------------------------------------------------------------------

Session PO.BCS01.17 - Mathematical Modeling and Statistical Methods

9:00 AM - 12:00 PM

6851 / 22 - Multi-cell type model for analyzing spatial single-cell protein imaging data with application to ovarian cancer

C. Sakitis, J. Laborde, J. Wrobel, A. C. Soupir, C. M. Colin-Leitzinger, B. G. Bitler, M. K. Townsend, A. B. Lawson, J. M. Schildkraut, S. S. Tworoger, K. L. Terry, L. C. Peres, B. L. Fridley

----------------------------------------------------------------------

Session PO.BCS01.17 - Mathematical Modeling and Statistical Methods

9:00 AM - 12:00 PM

6852 / 23 - Measure of three cell population co-localization for spatial protein imaging data analysis

K. Sabitov, A. Soupir, L. C. Peres, B. L. Fridley

----------------------------------------------------------------------

Session PO.CL05.07 - Immune Response to Therapies

9:00 AM - 12:00 PM

7747 / 7 - Comparison of T-cell activation status in patients treated with retifanlimab in combination with anti-LAG3/Anti-TIM3 vs retifanlimab alone

R.I. Haddad, D. Soulières, P. Neupane, A. Daste, Z. Dong, J. Lu, M. Kinder, J. Jackson, R. Schaub, N. Bourayou, J. Janik, C. L. Tourneau

----------------------------------------------------------------------

Session PO.CL01.11 - Liquid Biopsies: Circulating Nucleic Acids 5

9:00 AM - 12:00 PM

7823 / 4 - Ultrasensitive abnormal DNA methylation detection in plasma samples from patients with three different childhood sarcomas

G. Bonora, Z. Zhu, B. Xiang, K. Zhou, P. Du, S. Turaga, G. Samuel, A. Godwin

----------------------------------------------------------------------

Session PO.BCS01.13 - New Algorithms and Computational Methods

9:00 AM - 12:00 PM

6900 / 13 - Wakhan: Reconstruction of chromosome-scale copy number profiles of tumor genomes with long-read sequencing

T. Ahmad, A. Keskus, M. Kolmogorov, S. Aganezov, M. C. Dean, M. S. Farooqi, S. C. Sahinalp, B. Paten, K. H. Miga, Y. Liu, B. Yoo, A. A. Donmez, A. Goretsky, S. Maliki

----------------------------------------------------------------------

Session PO.CL01.06 - Biomarkers Predictive of Therapeutic Benefit 6

9:00 AM - 12:00 PM

7719 / 10 - Exploring biomarker predictors of response to nintedanib and bevacizumab combination therapy in advanced cancer patients: Correlative studies from Phase 1b study

R.K. Paluri, A. Kasi, F. Robert, G. Deep, A. Manne

----------------------------------------------------------------------

Session PO.BCS01.13 - New Algorithms and Computational Methods

9:00 AM - 12:00 PM

6906 / 19 - Test-time compute for subtype classification in pediatric T-cell acute lymphoblastic leukemia using transcriptomics

T.K. Mamidi, I. Pushel, B. Yoo, M. S. Farooqi, K. J. August

December 9, 2025

SS1-03; Topic 3: Obesity and breast cancer—The molecular link
Session Title: Special Session 1: Open Bar and All You Can Eat? The Impact of Lifestyle in Breast Cancer Risk and Recurrence
Time: 11:00 AM–12:30 PM CST
Location: Stars at Night 1-2
Speaker: Kristy A. Brown

RF2-05; Discussant for RF2-03 and RF2-04
Session Title: Rapid Fire 2
Time: 5:45 PM–6:45 PM CST
Location: Stars at Night 1-2
Speaker: Priyanka Sharma

PS1-13-10; Elucidating Stemness-Associated Regulatory Pathways to Guide Personalized Treatment for Ductal Carcinoma in Situ
Session Title: Poster Session 1
Time: 12:30 PM–2:00 PM CST, December 10, 2025
Location: Exhibit Hall
F. B. Behbod, E. Schueddig, V. Kochat, E. Arslan, Y. Dallas, P. Yang, R. Madan, Z. Y. Li, T. Fields, J. L. Wagner, K. Larson, C. Balanoff, A. Aripoli, A. Huppe, O. Winblad, J. Peterson, M. Hill, C. Smith, C. Fabian, E. J. Jeffers, D. C. Koestler, A. K. Godwin, L. J. Kilgore, M. T. Lewis, S. A. Khan, A. M. Thompson, K. Rai

PD6-06; Angiogenesis contributes to chemoimmunotherapy resistance in immune-high and immune-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial
Session Title: Poster Spotlight 6: Tools for Predicting Response and Outcomes with Neoadjuvant Therapy
Time: 7:00 AM–8:30 AM CST
Location: 301 ABC
P. Sharma, R. Yoder, J. M. Staley, R. Salgado, R. Madan, H. Pathak, A. K. Godwin, D. Koestler, Q. J. Khan, J. O’Shaughnessy, S. R. Stecklein

PD7-11; Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials
Session Title: Poster Spotlight 7: Early Triple Negative Breast Cancer—Biomarkers and Novel Approaches 
Time: 7:00 AM–8:30 AM CST
Location: 302 ABC
P. Sharma, R. Yoder, W. Cui, A. Winship, K. Hutt, S. Loi, Q. Khan, A. O’Dea, L. Nye, D. Satelli, J. Staley, R. Puri, A. Mitra, K.-A. Phillips, L. Alesi, Y. Lewis, J. O’Shaughnessy, H. Pathak, A. K. Godwin

SA2-03; Targeting non T-cells in the clinic
Session Title: State of the Art 2: Targeting the Non-T Cell Microenvironment
Time: 1:00 PM–2:15 PM CST
Location: Stars at Night 3-4
Speaker: George Plitas, Memorial Sloan Kettering Cancer Center, New York, NY
Patient Advocate: Cheryl Jernigan, PIVOT, University of Kansas Cancer Center

PS3-01-28; Effects of 6 Months of Tirzepatide on Risk Biomarkers for Development of Breast Cancer
Session Title: Poster Session 3
Time: 12:30 PM–2:00 PM CST
Location: Exhibit Hall
C. J. Fabian, C. R. Beaver, K. R. Powers, L. Ranallo, A. L. Kreutzjans, K. Pittman, C. Altman, T. Metheny, R. Biswell, A. Zelenchuk, H. Pathak, A. Mitra, A. K. Godwin, D. P. Mudaranthakam, E. D. Giles, S. D. Hursting, K. L. Cook, B. F. Kimler

PS5-08-20; A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007
Session Title: Poster Session 5
Time: 12:30 PM–2:00 PM CST
Location: Exhibit Hall
J. R. White, R. S. Cecchini, E. E. Harris, E. P. Mamounas, J. G. Bazan, D. G. Stover, P. A. Ganz, R. Jagsi, S. J. Anderson, C. Bergom, V. Théberge, M. B. El-Tamer, R. C. Zellars, D. A. Shumway, G. Chen, T. B. Julian, N. Wolmark 

December 6, 2025

133; Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Type: Oral Presentation
Location: OCCC - West Hall E2
Time: 9:30 AM - 9:45 AM EST
Hira Mian, Muhammad Salman Faisal, Tiening Chen, Ruta Brazauskas, Temitope Oloyede, Nausheen Ahmed, Aimaz Afrough, Larry Anderson, Rahul Banerjee, Jesús Berdeja, Aram Bidikian, Jakob Devos, Binod Dhakal, Ajoy Dias, Danai Dima, Yvonne Efebera, Lohith Gowda, Doris Hansen, Hamza Hashmi, Heather Landau, Lazaros Lekakis, Abu-Sayeef Mirza, Ravi Narra, Krina Patel, Ashley Rosko, Mark Schroeder, Surbhi Sidana, Saad Usmani, Marcelo Pasquini, Othman Akhtar, Taiga Nishihori, Meera Mohan

31; Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial 
Type: Oral Presentation
Location: OCCC – W224CDGH
Time: 9:30 AM – 11:00 AM EST
Xiaoming Zhong, Kathryn Roberts, Lindsey Montefiori, Zhuoxin Sun, Huimei Wei, Petri Polonen, Ti Cheng Chang, Wenchao Zhang, Shaohua Lei, Evadnie Rampersaud, Yiping Fan, Gang Wu, Ryan Mattison, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Martin Tallman, Jun Yang, Elisabeth Paietta, Selina Luger, Mark Litzow, Charles Mullighan

81; Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
Type: Oral Presentation
Location: OCCC - W414CD
Time: 10:00 AM - 10:15 AM EST
Andrew Kuykendall, Aniket Bankar, Kristen Pettit, Joseph Shatzel, Alessandro Lucchesi, Valentín García Gutiérrez, Jiri Mayer, Abdulraheem Yacoub, Harinder Gill, Antonin Hlusi, Daniel Sasca, Joseph Scandura, Marina Kremyanskaya, David Ross, Francesca Palandri, Maria Laura Fox, Alessandro Maria Vannucchi, Tamanna Haque, Steffen Koschmieder, Antonieta Sosa, Pedro Oyuela, Phil Dinh, Jie Xiao, Suneel Gupta, Sarita Khanna, Arturo Molina, Naveen Pemmaraju

170; Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506
Type: Oral Presentation
Location: OCCC – Sunburst Room (W340)
Time: 12:00 PM - 1:30 PM EST
Sameem Abedin, Victor Baidoo, Aniko Szabo, Richard Jones, Anurag Singh, Mark Litzow, John Wingard, Esperanza Papadopoulos, Alexander Perl, Robert Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey Uy, Edmund Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Heeje Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Caroline Chen, Nahla Hasabou, Mathew Rosales, Jason Hill, Stanley Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven Devine, Mary Horowitz, Yi-Bin Chen, Mark Levis, Mehdi Hamadani

173; Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis
Type: Oral Presentation
Location: OCCC - Sunburst Room (W340)
Time: 1:00 PM - 1:15 PM EST
Muhammad Kashif Amin, Moazzam Shahzad, Matthew McGuirk, Asma Zakir, Al-Ola Abdallah, Nausheen Ahmed, Sunil Abhyankar, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq 

239; Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes
Type: Oral Presentation
Location: OCCC – Valencia Room W415BC
Time: 2:00 PM – 3:30 PM EST
Guru Subramanian Guru Murthy, Yasmin Abaza, Somedeb Ball, Ramzi Abboud, Michael Haddadin, Jonathan Feld, Suresh Kumar Balasubramanian, Ashwin Kishtagari, Adam Cohen-Nowak, Veronica Guerra, Hayley Hawkins, Asmita Shukla, Virginia Tan, Dominika Dulak, Reema Tawfiq, Emily Dworkin, Julian Weiss, Amber Feng, Jesus Gonzalez-Lugo, Prajwal Dhakal, Jessica Leonard, Charles Foucar, Talha Badar, Rory Shallis, Annie Im, Shyam Patel, Chenyu Lin, Anand Patel, Eric Winer, Ehab Atallah, Rami Komrokji

292; Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium 
Type: Oral Presentation
Location: OCCC – Valencia Room W415A
Time: 2:00 PM – 3:30 PM EST
Christine McMahon, Deedra Nicolet, Alice Mims, Charles Foucar, Yazan Madanat, Brittany Ragon, Kieran Sahasrabudhe, Onyee Chan, Joshua Zeidner, Michael Hochman, Daniel Pollyea, Krzysztof Mrózek, Michael Walker, Fnu Amritpal Singh, Tara Lin, Bianca Barredo, Lauren Banaszak, Jesus Gonzalez-Lugo, Alex Ambinder, Ann-Kathrin Eisfeld

294; Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium
Type: Oral Presentation
Location: OCCC – Valencia Room W415A
Time: 2:00 PM – 3:30 PM EST
Jesus Gonzalez-Lugo, Alex Ambinder, Deedra Nicolet, Krzysztof Mrózek, Maire Okoniewski, Yazan Madanat, Michael Walker, Charles Foucar, Christine McMahon, Michael Hochman, Brittany Ragon, Joshua Zeidner, Kieran Sahasrabudhe, Anna Bode, Bianca Barredo, Lauren Banaszak, Rami Komrokji, Alice Mims, Onyee Chan, Tara Lin, Ann-Kathrin Eisfeld

226; Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study 
Type: Oral Presentation
Location: OCCC – Tangerine Ballroom F2
Time: 2:00 PM – 3:30 PM EST 
Chan Cheah, Manish Patel, Toby Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo Ma, Jonathon Cohen, Krish Patel, Jennifer Brown, Lydia Scarfo, Talha Munir, Ewa Lech-Maranda, Marc Hoffmann, Chaitra Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine Tam, Joanna Rhodes, Julie Vose, Matthew McKinney, James Gerson, Minal Barve, Bryone Kuss, Youngil Koh, Aisling Barrett, Steven Treon, Jorge Castillo, John Seymour, Amy Ruppert Stark, Samuel McNeely, Richard Walgren, Donald Tsai, Katherine Bao, Binoj Chandrasekharan Nair, Jennifer Woyach, Lia Palomba 

400; Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.
Type: Oral Presentation
Location: OCCC – W224ABEF
Time: 4:00 PM – 5:30 PM EST
Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

2689; Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Moazzam Shahzad, Farooq Ashraf, Sayyam Razzaq, Hafiz Muhammad Hannan Javed, Muhammad Shaheer Mannan, Muhammaf Fareed Khalid, Fatima Sial, Atif Butt, Anas Al-sadi, Ibrahim Khamees, Sarmad Zaman Warraich, Michael Jaglal, Muhammad Umair Mushtaq

2715; Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Yannis Valtis, Karamjeet Sandhu, Rawan Faramand, Amy Zhang, Katharine Miller, LaQuisa Hill, Ibrahim Muhsen, Tamer Othman, Marlise Luskin, Evan Chen, Caspian Oliai, Georgia Lill, Ryan Cassaday, Noam Kopmar, Aaron Logan, Matthew Connor, Talal Hilal, Jae Park, Melhem Solh, Caitlin Guzowski, Jessica Leonard, Virginia Tan, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Muthu Kumaran, Rasmus Hoeg, Divya Koura, Kaitlyn Dykes, Wendy Stock, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Kristen O'Dwyer, Jozal Moore, Matthew Ulrickson, Ali Al-Darobi, Ken Byrd, Stephanie Tsai, Timothy O'Connor, Eunice Wang, Ross McCauley, Omer Jamy, Razan Mohty, Gregory Roloff, Katherine Sutherland, Ibrahim Aldoss, Bijal Shah, Lori Muffly, Noelle Frey

2396; CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

2460; Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using posttransplant cyclophosphamide-based gvhd prophylaxis
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Moazzam Shahzad, Aqeeb Ur Rehman, Aroog Khaliq, Muhammad Kashif Amin, Jordan Leal, Olivia Molander, Philip Lubanski, Maggie Nelson, Abdulraheem Yacoub, Anurag Singh, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

2793; Rising mortality trends in elderly multiple myeloma patients with hypertension: A CDC wonder database analysis (1999–2023)
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Rehan Ishaque, Zauha Fawad Memon, Abdul Basit Khan, Matia Fawad Memon, Sibgha Fawad Memon, Abdul Subhan Talpur, Fawad Talat, Irfan Ahmad, Muhammad Kashif Amin, Muhammad Umair Mushtaq, Aswanth Reddy, Abdelhamid Benselma 

2831; Optimal dose and duration of venetoclax for induction therapy in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Mamoon Ahmed, Farooq Ashraf, Anas Al-sadi, Muhammad Shaheer Mannan, Jehad Zeidalkilani, Hafsa Shahid, Aniqa Faraz, Maheen Zahid, Aman Ullah, Sohaib Irfan, Sarmad Zaman Warraich, Muhammad Umair Mushtaq, Moazzam Shahzad

1333; Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Farooq Ashraf, Hafiz Muhammad Hannan Javed, Sarmad Zaman Warraich, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

2051; A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant– selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Jason Gotlib, John Mascarenhas, Raajit Rampal, Abdulraheem Yacoub, Hongfei Li, Josu Santamaria, Molly Halloran, Naveen Pemmaraju

2707; Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell, Miguel-Angel Perales, Joseph McGuirk, Stephen Schuster, David Porter, Jamie Brower, Hanan Alharthy, Sairah Ahmed, Richard Maziarz, Veronika Bachanova, Olalekan Oluwole, Anthony Hunter, Peter Riedell

2851; Impact of pre-transplant anxiety and depression on outcomes of AML patients after allogeneic transplantation 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Neda Amirmokhtari, Hannah Katz, Elizabeth Muenks, Jianzheng Wu, Joseph McGuirk, Tara Lin

1549; Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Bhavana Bhatnagar, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Selina Luger, Charles Mullighan, Martin Tallman, Mark Litzow 

1626; Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Onyee Chan, Michael Walker, Deedra Nicolet, Krzysztof Mrózek, Najla Al Ali, Christine McMahon, Jesus Gonzalez-Lugo, Joshua Zeidner, Brittany Ragon, Charles Foucar, Yazan Madanat, Kieran Sahasrabudhe, Bianca Barredo, Lauren Banaszak, Andres Gomez-De Leon, Michael Hochman, Douglas Tremblay, Michael Haddadin, Tara Lin, Jeffrey Lancet, Rami Komrokji, Elaine Mardis, Alex Ambinder, Alice Mims, Ann-Kathrin Eisfeld

2373; Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Yuanli Lei, Muhammad Atif Khan, Aqsa Ashraf, Noha Soror, Muhammad Salman Faisal, Jennifer Holter-Chakrabarty, Adam Asch, Forat Lutfi, Rachel Dileo, Sami Ibrahimi, Manu Pandey, Mohamad Khawandanah, Silas Day, Huimin Wu, Prerna Mewawalla, Nausheen Ahmed, Taha Al-Juhaishi

1798; Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Ajay Major, Diana Abbott, Jordan Snyder, Nausheen Ahmed, Alline Amorim, Jose Villasboas Bisneto, John Sharp, Timothy Voorhees, Samin Houshyar, Danielle Wallace, Arjab Adhikari, Dilan Patel, Christopher Wanjiku, Charlotte Wagner, Allison Bock, Taylor Brooks, Haya Al Any, Mazie Tsang, Mohamed Rajab, Madiha Iqbal, Nidhi Desai, Supriya Gupta, Nicole Altomare, Reem Karmali, Daniel Trotier, Priyanka Pophali, Edd Ricker, Hua-Jay Cherng, Arjun Gupta, Brian Hill

2339; Pre-infusion ADAMTS13 and VWF levels are associated with clinical outcomes of patients receiving CAR-T cell therapy
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Abdalla Shoaib, Sarah Gralnek, Forat Lutfi, Haitham Abdelhakim, X. Long Zheng

1846; Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Haitham Abdelhakim, Geoffrey Shouse, Manali Kamdar, Priyanka Pophali, Samuel Yamshon, Luke Mountjoy, Aravind Ramakrishnan, Ian Flinn, Akiva Diamond, Margaret Gilbert, Maria-Bernadette Madel, Laura Angelo, Hettie Stein, Deb Chapman, Patricia Allison, John Gutheil, Teresa Melink, Susie Bergman, Mary Newman, Helen Heslop, Malcolm Brenner, Premal Lulla, Monic Stuart, Juan Vera

2239; Predictors of renal recovery in newly diagnosed multiple myeloma with light chain cast nephropathy 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Jeet Patel, Jeries Kort, Al-Ola Abdallah, Evguenia Bhurtel, Michael Weise, Jordan Snyder

2389; Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Paul Worsley, Jianzheng Wu, Isuru Ratnayake, Dinesh Mudaranthakam, Al-Ola Abdallah, Jeries Kort, Evguenia Bhurtel, Leyla Shune, Joseph McGuirk, Muhammad Nashatizadeh, Nausheen Ahmed, Forat Lutfi

2501; Vancomycin-resistant enterococci (VRE) colonization is associated with worse outcomes post allogenic hemopoietic stem cell transplantation 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 5:30 PM - 7:30 PM EST
Haitham Abdelhakim, Abdalla Shoaib, Marwa Elsayed, Nadia Ghallab, Leyla Shune, Anurag Singh, Shaun DeJarnette, Anthony Sung, Joseph McGuirk, Sunil Abhyankar

December 7, 2025

Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma
Type: Friday Satellite Symposia; Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Patients with Acute Myeloid Leukemia
Location: Hyatt - Regency Ballroom R
Time: 7:00 AM - 10:00 AM EST
Speaker: Tara L Lin

505; Impact of conditioning intensity on outcomes after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis 
Type: Oral Presentation
Location: OCCC - W331
Time: 9:30 AM - 9:45 AM EST
Muhammad Kashif Amin, Moazzam Shahzad, Amir Kasaeian, Hediyeh Alemi, Asma Zakir, Haitham Abdelhakim, Anurag Singh, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

468; Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update 
Type: Oral Presentation
Location: OCCC – West Hall D2
Time: 9:30 AM – 11:00 AM EST
Stephen Schuster, Catherine Thieblemont, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter Riedell, Phoebe Joy Ho, José Antonio Pérez-Simón, Andy Chen, Loretta Nastoupil, Bastian von Tresckow, Andrés José María Ferreri, Takanori Teshima, Piers Patten, Joseph McGuirk, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Aiesha Zia, Rakesh Awasthi, Roberto Ramos, Meryem Ktiouet Dawson, Pei Hsu, Darragh O'Donovan, Nathan Fowler, Martin Dreyling

476; Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results 
Type: Oral Presentation
Location: OCCC – Tangerine Ballroom F3-4
Time: 9:30 AM - 11:00 AM EST
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos

453; Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study
Type: Oral Presentation
Location: OCCC – Valencia Room W415A
Time: 9:30 AM - 11:00 AM EST
Curtis Lachowiez, Andy Kaempf, Jad Othman, Seongseok Yun, Mael Heiblig, Michael Heuser, Rabia Shahswar, Anand Patel, Rafael Madero-Marroquin, Joseph Cannova, Irene Zacheo, Federica Monaco, Dimitrios Drekolias, Fatima Tuz Zahra, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Nicola Long, Rachel Cook, Elie Traer, Ronan Swords, Jennifer Saultz, Jenny O'Nions, Faisal Basheer, John Laurie, Shivani Handa, Eytan Stein, Maria Baer, Wendy Stock, Rebecca Olin, William Blum, Gary Schiller, Tara Lin, Emily Curran, Ying Huang, Rina Welkie, Ashley Yocum, Giovanni Marconi, Ellen Madarang, Justin Watts, Yazan Madanat, Richard Dillon, Sanam Loghavi, Joshua Zeidner, Daniel Pollyea, Elsa Bernard

483; A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1
Type: Oral Presentation
Location: OCCC - W414AB
Time: 10:00 AM - 10:15 AM EST
Andrew Kuykendall, Rupali Roy, Abdulraheem Yacoub, Marina Kremyanskaya, Aaron Gerds, Ronald Paquette, Jeanne Palmer, Kathryn Johnson, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Ashley Yu, Rami Komrokji, Raajit Rampal, Ruben Mesa, Ronald Hoffman, John Mascarenhas 

484; Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Type: Oral Presentation
Location: OCCC - W414AB
Time: 10:15 AM - 10:30 AM EST
John Mascarenhas, Haifa Kathrin Al-Ali, Vikas Gupta, Haris Ali, Francesca Palandri, Francesco Passamonti, Raajit Rampal, Aaron Gerds, Tania Jain, Sanjay Mohan, Steffen Koschmieder, Caroline McNamara, Andrew Perkins, Bethan Psaila, Vincent Ribrag, William Shomali, Rosa Ayala Diaz, Mikkel Helleberg Dorff, Claire Harrison, Stephen Oh, Frank Stegelmann, Alessandro Maria Vannucchi, Abdulraheem Yacoub, Jason Gotlib, Jyoti Nangalia, Chenwei Tian, Betty Lamothe, Erin Crowgey, Tatiana Zinger, Evan Braunstein, David Ross

479; Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase ½ study extended follow-up Results
Type: Oral Presentation
Location: OCCC - Tangerine Ballroom F3-4
Time: 10:30 AM - 10:45 AM EST
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos

516; Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world
Type: Oral Presentation
Location: OCCC - Chapin Theater (W320)
Time: 10:45 AM - 11:00 AM EST
Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

444; Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, phnegative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival
Type: Oral Presentation
Location: OCCC - W224ABEF
Time: 10:45 AM - 11:00 AM EST
Matthew Wieduwilt, Jun Yin, Oudom Kour, Rebecca Teske, Wendy Stock, Carolin Escherich, Jun Yang, Zhenhua Li, Ken Byrd, Kimberley Doucette, James Mangan, Scott Hall, Alice Mims, Katarzyna Jamieson, Shira Dinner, Ali Bseiso, Georgia Giordano, Caner Saygin, Geoffrey Uy, Mark Litzow, Richard Stone

Immune Checkpoint Blockade as a Strategy for Reversing Hematologic Aging
Type: Scientific Workshops; Engineering the Immune System to Reverse Hematologic Aging
Location: OCCC - W312
Time: 3:44 PM - 4:25 PM EST
Speaker: Haitham Abdelhakim, MD

3890; Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Jacob Soumerai, Stephen Opat, Chan Cheah, Mazyar Shadman, Emma Verner, Monica Tani, Marc Hoffmann, Lori Leslie, Shuo Ma, Yiqian Fang, Gabriel Man, Binghao Wu, Charity Henrich, Sheel Patel, Remus Vezan, Constantine Tam

3671; Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Yun Kyoung Tiger, Charlotte Zuber, Venkata Preetam Sandeep Kaduluri, Taylor Kujawa, Mollie Reese, Joseph Lukowski, Matthew Gromowsky, Maun Baral, Graham Wehmeyer, Joshua Friedman, Vidiya Srikakulapu, Ross Terada, Mia Willingham, Benjamin Hane, Youssef Youssef, Michele Stanchina, Juan Alderuccio, Timothy Voorhees, Joseph Bennett, Marc Hoffmann, Thomas Ollila, Praveen Ramakrishnan Geethakumari, Adam Kittai, Dilan Patel, Christopher D'Angelo, Chris Dittus, Narendranath Epperla, Cole Sterling, Andrew Evens, Matthew Matasar, Adam Olszewski

4198; Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study.
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM – 8:00 PM EST
Kayleigh Ingersoll Omdahl, Steven Siegel, Jiayi Dong, Susan DeWolf, Kyle Hebert, Donna Neuberg, Isabella Schichter, Alexandre Albanese, Paul Keskula, Lorenzo Cagnin, Kristy Applegate, Merav Bar, Saurabh Chhabra, Sung Choi, William Clark, Suman Das, Robert Jenq, Richard Jones, John Levine, Brent Logan, Michael Martens, Hemant Murthy, Armin Rashidi, Marcie Riches, Wael Saber, Karamjeet Sandhu, Anthony Sung, Karilyn Larkin, Monzr M. Al Malki, Mahasweta Gooptu, Hany Elmariah, Amin Alousi, Lyndsey Runaas, Brian Shaffer, Andrew Rezvani, Najla El Jurdi, Alison Loren, Mary Horowitz, Javier Bolanos-Meade, Shernan Holtan, Ami Bhatt, Miguel-Angel Perales, Leslie Kean, Lindsey Roeker, Toby Eyre

3415; A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Geoffrey Uy, Jun Yin, Shira Dinner, Meagan Jacoby, Daniel Deangelo, Jane Liesveld, Jonathan Kolitz, Adam Asch, Olatoyosi Odenike, Oudom Kour, Korrie Skogen, Ken Byrd, Richard Little, Steven Gore, Andrew Carroll, Krzysztof Mrózek, John Byrd, Ann-Kathrin Eisfeld, Anthony Jaslowski, Harry Erba, Mark Litzow, Wendy Stock, Richard Stone

3365; KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (BALL) treated with brexucabtagene autoleucel (Brexu-cel)
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

4200; Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Moazzam Shahzad, Shah Rukh, Aroog Khaliq, Aqeeb Ur Rehman, Amna Bint I Munir, Muhammad Kashif Amin, Amir Kasaeian, Anthony Sung, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

4619; Comparative trends in mortality from acute lymphoblastic and Acute Myeloid Leukemia in the United States: A CDC wonder analysis (1999–2020)
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Zauha Fawad Memon, Sibgha Fawad Memon, Rehan Ishaque, Sarmad Masaud, Matia Fawad Memon, Amna Ikram, Shajadi Patan, Furqan Tarique Memon, Muhammad Kashif Amin, Joseph McGuirk, Muhammad Umair Mushtaq, Moazzam Shahzad

4254; Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Moazzam Shahzad, Muhammad Kashif Amin, Amir Kasaeian, Hediyeh Alemi, Kayla Pfannenstiel, Anurag Singh, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

764; Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007
Type: Oral Presentation
Location: OCCC – Chapin Theater (W320)
Time: 10:30 AM – 12:00 PM EST
Ghayas Issa, Amir Fathi, Amer Zeidan, Harry Erba, Gail Roboz, Jessica Altman, Keith Pratz, Mark Juckett, Tara Lin, Suresh Kumar Balasubramanian, Anjali Advani, Gary Schiller, Neil Palmisiano, Marcello Rotta, Stephen Strickland, Christine McMahon, Yazan Madanat, Talha Badar, Mohamad Khawandanah, George Yaghmour, James McCloskey, James Mangan, Antoine Saliba, Ivana Gojo, Diaa Osman, Hongling Zhang, Ying Tian, Marcie Riches, Daniel Corum, Mollie Leoni, Eunice Wang

790; Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes
Type: Oral Presentation
Location: OCCC - Valencia Room W415A
Time: 11:15 AM - 11:30 AM EST
Guillermo Garcia-Manero, Lalit Saini, Amer Zeidan, Abdulraheem Yacoub, Lori Maness, Elie Traer, James Foran, Sanjay Mohan, Michael Lübbert, Tom Lodewyck, Blanca Xicoy, Harshad Amin, Kimo Bachiashvili, Habte Yimer, Nancy Zhu, Haifa Kathrin Al-Ali, Patricia Font Lopez, Guillermo Sanz, Valeria Santini, Jesús Berdeja, Victor Priego, Olatoyosi Odenike, Bert Heyrman, David Valcarcel, Yubing Wan, Winny Chan, Aram Oganesian, Yuri Sano, Harold Keer, Elizabeth Griffiths

934; Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis 
Type: Oral Presentation
Location: OCCC - W331
Time: 3:30 PM - 3:45 PM EST
Amir Kasaeian, Moazzam Shahzad, Zeeshan Sattar, Muhammad Kashif Amin, Hediyeh Alemi, Forat Lutfi, Mehdi Hamadani, Rajat Bansal, Alma Habib, Joseph McGuirk, Muhammad Umair Mushtaq 

1075; Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies
Type: Oral Presentation
Location: OCCC – W224ABEF
Time: 4:30 PM - 6:00 PM EST
Chenyu Lin, Melinda Chen, Jingchen Chai, Janvi Jani, Sashi Kolli, Daniel Schrum, Erin Eberwein, Catie Cash, Jen Tichon, Amy Bush, Lauren Hill, Joey Misuraca, Matthew McKinney, Gwynn Long, Cristina Gasparetto, Taewoong Choi, Sendhilnathan Ramalingam, Suzanne Kirby, Thomas LeBlanc, Andrea Sitlinger, Anthony Sung, Raul Torres, Kellie Rutledge, Matthew Ream, John Gannon, Yubin Kang, Stefanie Sarantopoulos, Mitchell Horwitz, Jenifer Siegelman, Ruth Phillips, Sin-Ho Jung, Erik Koenig

981; Upfront therapy with allogeneic hematopoietic stem cell transplantation versus DNA methyltransferase inhibitors in patients with vexas syndrome: A comparative matched cohort efficacy analysis of 39 patients
Type: Oral Presentation
Location: Hyatt – Plaza Int’l HUK
Time: 4:30 PM – 6:00 PM EST
Saubia Fathima, Ali Alsugair, Kimberly Langer, Terra Lasho, Christy Finke, Mark Litzow, Aasiya Matin, Urshila Durani, Mehrdad Hefazi Torghabeh, William Hogan, Mithun Shah, Ronald Go, Gabriel Bartoo, Jade Kutzke, Kristen McCullough, Matthew J Koster, Kenneth Warrington, Kaaren Reichard, Horatiu Olteanu, Yael Kusne, Jeanne Palmer, Saurabh Chhabra, Mary Riwes, Joseph McGuirk, Elizabeth Krakow, Amelia Langston, Taxiarchis Kourelis, David Dingli, Mrinal Patnaik, Hassan Alkhateeb, Abhishek Mangaonkar

1058; Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib 
Type: Oral Presentation
Location: OCCC – Valencia Room W415A
Time: 4:30 PM – 6:00 PM EST
Mark Levis, Mehdi Hamadani, Brent Logan, Richard Jones, Anurag Singh, Mark Litzow, John Wingard, Esperanza Papadopoulos, Alexander Perl, Robert Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey Uy, Edmund Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Heeje Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Caroline Chen, Nahla Hasabou, Mathew Rosales, Jason Hill, Stanley Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven Devine, Mary Horowitz, Yi-Bin Chen

995; RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA 
Type: Oral Presentation
Location: OCCC – W414AB
Time: 4:30 PM - 6:00 PM EST
Fieke Hoff, Alexander Li, Ying Huang, Rina Welkie, Ronan Swords, Elie Traer, Eytan Stein, Tara Lin, Maria Baer, Vu Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Joshua Zeidner, Rebecca Olin, Catherine Smith, Gary Schiller, Emily Curran, Shivani Handa, Nyla Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Marcus, Leonard Rosenberg, Brian Druker, Ross Levine, Ashley Yocum, Uma Borate, Alice Mims, John Byrd, Yazan Madanat

957; Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience 
Type: Oral Presentation
Location: OCCC – W414AB
Time: 4:30 PM - 6:00 PM EST
Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

1024; Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia
Type: Oral Presentation
Location: OCCC - West Hall D2
Time: 5:15 PM - 5:30 PM EST
Vikas Gupta, John Mascarenhas, Haris Ali, David Ross, Abdulraheem Yacoub, Tania Jain, Lynette Chee, Aaron Gerds, Jean-Jacques Kiladjian, Ruben Mesa, William Shomali, Makoto Yoshimitsu, Rosa Ayala Diaz, Chi-Joan How, Steffen Koschmieder, Caroline McNamara, Yosuke Nakaya, Francesca Palandri, Professor Francesco Passamonti, Andrew Perkins, Bethan Psaila, Raajit Rampal, Natasha Szuber, Frank Stegelmann, Alessandro Maria Vannucchi, Hiroki Yamaguchi, Jason Gotlib, Jyoti Nangalia, Chenwei Tian, Betty Lamothe, Erin Crowgey, Tatiana Zinger, Evan Braunstein, Claire Harrison

6403; Social determinants of health and outcomes in patients with acute leukemia: Interim results from a prospective, single institution study 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Maire Okoniewski, Tara Lin, Jianzheng Wu, Ken Byrd, Jesus Gonzalez-Lugo, Dinesh Mudaranthakam, Heather Male 

5198; A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Justin Watts, Gautam Borthakur, Tara Lin, Nashat Gabrail, Kruti Patel, Yazan Madanat, Joshua Zeidner, Noor Khaskhely, Lynn Bonham, Michelle Nelson, John Kumer, Daphne Taylor, Caroline Taromino, Miriam Weber Miller, Dirk Huebner, Michael Maris

5215; Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Thomas LeBlanc, Amir Ali, Victoria Campbell, Onyee Chan, Thomas Coats, Doria Cole, Daniel Cuadras, Nicholas Cunningham, Yngvar Floisand, Gillian Flynn, Jesus Gonzalez-Lugo, Katherine Hodgson, Anjum Khan, Kristin Koenig, Catherine Lai, Alex Legg, Mimi Lo, Amanda Lopez, Mark Lynam, Jamie Maddox, Sateesh Nagumantry, Matthew Newman, Jenny O'Nions, Saemi Park, Montse Pedrós, Giuseppe Piccoli, Melisa Stricherz, David Taussig, Charlotte Wagner, Eunice Wang, Richard Whitmill, George Yaghmour, Rui Zhao, Priyanka Mehta

5157; A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Nilesh Kapoor, Deedra Nicolet, Krzysztof Mrózek, Najla Al Ali, Alex Ambinder, Julia Anderson, Lauren Banaszak, Bianca Barredo, Onyee Chan, Charles Foucar, Andres Gomez-De Leon, Jesus Gonzalez Lugo, Nicole Lux, Christine McMahon, Brittany Ragon, Kieran Sahasrabudhe, Joshua Zeidner, Alice Mims, Ann-Kathrin Eisfeld, Yazan Madanat

5120; Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Anjali Advani, Li Chen, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Dan Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Selina Luger, Charles Mullighan, Martin Tallman, Mark Litzow

5944; MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Geoffrey Shouse, Samuel Yamshon, Manali Kamdar, Haitham Abdelhakim, Priyanka Pophali, Luke Mountjoy, Aravind Ramakrishnan, Ian Flinn, Akiva Diamond, Margaret Gilbert, Maria-Bernadette Madel, Laura Angelo, Hettie Stein, Deb Chapman, Patricia Allison, John Gutheil, Teresa Melink, Susie Bergman, Mary Newman, Helen Heslop, Malcolm Brenner, Premal Lulla, Monic Stuart, Juan Vera

6375; Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Arash Velayati, Alexandria Jensen, Danai Dima, Masooma Rana, Lauren Peres, Leyla Shune, Brett Reid, Oren Pasvolsky, Andrew Portuguese, Nadine Abdallah, Hitomi Hosoya, Lekha Mikkilineni, Rahul Banerjee, Raffaella Cassano Cassano, Jack Khouri, Christopher Ferreri, Aimaz Afrough, Noa Biran, Sneha Purvey, Gliceida Fortuna, Vanna Hovanky, Douglas Sborov, Kelley Julian, Kimberly Green, Ciara Louise Freeman, Joseph McGuirk, Eli Zolotov, Cindy Varga, Marcus Geer, Omar Puglianini, Utkarsh Goel, Mahmoud Gaballa, Faiz Anwer, Shahzad Raza, Christen Dillard, Saurabh Zanwar, Saurabh Dahiya, David Miklos, James Davis, Megan Herr, Melissa Alsina, Yi Lin, Peter Voorhees, Ran Reshef, Larry Anderson, Krina Patel, Doris Hansen, Surbhi Sidana 

6320; Comparative safety and efficacy of bendamustine versus fludarabine/cyclophosphamide prior to chimeric antigen receptor- T cell therapy: A systematic review and meta-analysis 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Muhammad Kashif Amin, Tehseen Raza, Hira Habib, Nabeeha Noor, Muhammad Usman, Fatima Imran, Rameen Fatima, Muhammad Zohaib Qasim, Hammad Shafi, Moazzam Shahzad, Joseph McGuirk, Muhammad Umair Mushtaq

6269; Mortality trends of chronic lymphocytic leukemia and pneumonia in the United States (1999–2023): A CDC-wonder analysis
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Sibgha Fawad Memon, Zauha Fawad Memon, Abdul Basit Khan, Rehan Ishaque, Matia Fawad Memon, Abdul Subhan Talpur, Fawad Talat, Muhammad Shaheer Mannan, Aswanth Reddy, Muhammad Kashif Amin, Muhammad Umair Mushtaq, Moazzam Shahzad, Supratik Rayamajhi

5526; Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
Naveen Pemmaraju, Ellen Ritchie, John Mascarenhas, Salman Fazal, Erin Crowgey, TaeHyung (Simon) Kim, J.E. Hamer-Maansson, Tricia Kalafut, Evan Braunstein, Abdulraheem Yacoub

5590; Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM - 8:00 PM EST
John Mascarenhas, Justin Johnson, Heidi Kosiorek, Megan Metzger, Tiziano Barbui, Josef Prchal, Alessandro Rambaldi, Abdulraheem Yacoub, Ashley Yu, Ruben Mesa, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, Mohamed Salama

5840; Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM – 8:00 PM EST
Saad Usmani, Michał Mielnik, Aránzazu Alonso Alonso, Al-Ola Abdallah, Mamta Garg, Wojciech Janowski, Youngil Koh, Chang-Ki Min, Enrique Ocio, Hang Quach, Karthik Ramasamy, Albert Oriol, Paula Rodriguez-Otero, Ricarda Garcia Sanchez, Irwindeep Sandhu, Katja Weisel, Chris Brawley, Miguel Murillo, Fernando Carreño, Jacqueline Egger, Morrys Kaisermann, Marek Hus

5820; Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM – 8:00 PM EST
María-Victoria Mateos, Vania Hungria, Meral Beksac, Pawel Robak, Kihyun Kim, Sergei Voloshin, Hanlon Sia, Esther González García, Gracia Martinez, Chang-Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špička, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Ward, Phoebe Joy Ho, Roman Hajek, Sebastian Grosicki, Syed Zafar, Al-Ola Abdallah, Jorge Mouro, Zeyad Khalaf, Hena Baig, Ainslee Moore, Chee Paul Lin, Maureen Nichols, Ianire Garrobo-Calleja, Sybil Varghese, Nick Pirooz, Joe Lee, Lydia Eccersley, Elisabet Manasanch, Ludek Pour, Meletios Dimopoulos 

5985; Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM – 8:00 PM EST
Aqeeb Ur Rehman, Moazzam Shahzad, Shah Rukh, Zeeshan Sattar, Muhammad Kashif Amin, Jeries Kort, Al-Ola Abdallah, Leyla Shune, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

6024; Outcomes after bone marrow versus peripheral blood matched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based gvhd prophylaxis 
Type: Poster Presentation
Location: OCCC - West Halls B3-B4
Time: 6:00 PM – 8:00 PM EST
Amna Bint I Munir, Aqeeb Ur Rehman, Moazzam Shahzad, Muhammad Kashif Amin, Anurag Singh, Sunil Abhyankar, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

*The below content was pulled from currently available information on ASTRO's website as well as supplied by KU Cancer Center members.

September 28, 2025

Impact of Intensified Survivorship Care Planning on Cardiovascular Care in Prostate Cancer Survivors: Primary Results of NRG-CC007CD

Session Date/Time: Sunday, September 28, 2025, 4:45 - 4:55 p.m.

Speaker: Ron Chen, MD, MPH, FASCO, FASTRO

Abstract

May 31, 2025

Antibody-Drug Conjugates in Urothelial Carcinoma: Bridging Innovation and Community Practice

8:00 AM – 9:15 AM CDT

Hall D2 | Live Stream

Education Session
Session Title: State of the Science: Advancing Frontiers—Novel Diagnostics and Therapeutics in Renal Cell Carcinoma and Urothelial Carcinoma

Track: Genitourinary Cancer—Kidney and Bladder
Presenter: Elizabeth Marie Wulff-Burchfield, MD

A phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first line treatment of advanced pancreatic cancer (PANCONVA trial).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #: TPS4229; Poster Bd #505a
Anup Kasi, Raed Al-Rajabi, Fairooz Kabbinavar, Nancy Sherman, Haoran Li, Milind Phadnis, Shannon Bradbury, Cathey Belcher, Jordan Rose, Ramanand Subramanian, Manidhar Reddy Lekkala, Timothy Schmitt, Sean Kumer, Clay King, Mojtaba Olyaee, Amit Rastogi, Reza Hejazi, Joaquina Baranda, Weijing Sun

Development of a cfDNA-based protein-informed epigenetic signature (PEp-sig) to enable biomarker-based risk stratification for pancreatic ductal adenocarcinoma (PDA).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #4149; Poster Bd #439
Ashish Manne, Lianbo Yu, Adam Khorasanchi, Timothy Pawlik, Jordan Cloyd, Ravi Paluri, Kannan Thanikachalam, Anup Kasi, Ashwini Esnakula, Anne Noonan, Arjun Mittra, Ning Jin, Shafia Rahman, John Hays, Susan Tsai, Sravan Jeepalyam, Deepak Sherpally, Wancai Yang

Repurposing itraconazole for secondary prevention of metaplasia and primary prevention of cancer in patients with high-risk Barrett's esophagus in combination with ablation.
9:00 AM – 12:00 PM CDT

Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #TPS4212; Poster Bd 496b
Ajay Bansal, Sohini Samaddar, Nicholas Shaheen, Amit Rastogi, Prashanthi Thota, Vani Konda, Dayna Early, Amitabh Chak, Ananda Sen, Scott Schuetze, Luz Rodriguez Traver, Ellen Richmond, Anila Katragadda, Asad Umar, Dean Brenner, Rashna Madan, David Wang, Dominique Bounds, Souvik Saha

Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.
9:00 AM – 12:00 PM CDT

Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #4177; Poster Bd #467
Anup Kasi, Jose Iglesias

A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #4115; Poster Bd #405
Anita Turk, Noah Graham, Dustin Deming, Devalingam Mahalingam, Anup Kasi, Suneel Kamath, Kathryn Hourdequin, Peter O'Dwyer

A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Pediatric Oncology
Track: Pediatric Oncology
Abstract #10054; Poster Bd #169
Kathryn Sutton, Kevin Ginn, Zhulin He, Lindsey Hoffman, William Petersen, Emi Caywood, Muna Qayed, Stacy Senn, Cynthia Wetmore, Howard Katzenstein, Thomas Cash

Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.
9:12-9:18 PM CDT
E450a | On Demand
Rapid Oral Abstract Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #7017
Michael Wang, Marc Hoffmann, Tomasz Wrobel, Marek Trneny, David Belada, Fatih Demirkan, Panayiotis Panayiotidis, Wojciech Jurczak, Pier Zinzani, Mary-Margaret Keating, Sung-Soo Yoon, Miklos Egyed, Constantine Tam, Nathalie Johnson, Edith Szafer-Glusman, Jennifer Lin, James Dean, Jutta Neuenburg, Gottfried von Keudell

Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: A systematic review and meta-analysis.
1:30 PM – 4:30 PM CDT

Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Lung Cancer—Non-Small Cell Metastatic
Track: Lung Cancer
Abstract #8576; Poster Bd #56
Parth Sharma, Mangesh Kritya, Vasu Bansal, Priyanka Sharma, Himil Mahadevia, Anuj Shrestha

Acolbifene vs tamoxifen for breast cancer prevention in premenopausal women at high risk for breast cancer.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Prevention, Risk Reduction, and Genetics
Track: Prevention, Risk Reduction, and Genetics
Abstract #TPS10628; Poster Bd #350b
Carol Fabian, Bruce Kimler, Ananda Sen, Dean Brenner, Scott Schuetze, Seema Khan, Lisa Yee, Sagar Sardesai, Eileen Dimond, Marjorie Perloff, Brandy Heckman-Stoddard

Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Quality Care/Health Services Research
Track: Care Delivery and Quality Care
Abstract #11147; Poster Bd #486
Erin Cobain, Priyanka Sharma, Kent Hoskins, Michael Berry, Gregory Vidal, J. Jaime Alberty-Oller, Nicole Gordon, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy

Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Lung Cancer—Non-Small Cell Metastatic
Track: Lung Cancer
Abstract #TPS8649; Poster Bd #128a
Benjamin Solomon, Wallace Akerley, Vinod Ganju, Jun Zhang, Alex Adjei, Melissa Johnson, Alexander Spira, Lei Deng, Edward Garon, So Yeon Kim, Richard Frank, Lyudmila Bazhenova, Rasha Cosman, Rachel Roberts-Thomson, Christos Karapetis, Yong Ben, Foster Gonsalves

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).
4:24-4:36 PM CDT
Hall D1 | Live Stream
Oral Abstract Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #LBA4005
Vincent Picozzi, Hani Babiker, Sreenivasa Chandana, Bohuslav Melichar, Anup Kasi, Gang Jin, Javier Gallego, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Arsen Osipov, Christelle De La Fouchardiere, Tomislav Dragovich, Woo Jin Lee, Kynan Feeney, Philip Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Teresa Macarulla

Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.

9:12-9:18 PM CDT
E450a | On Demand
Rapid Oral Abstract Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #7017
Michael Wang, Marc Hoffmann, Tomasz Wrobel, Marek Trneny, David Belada, Fatih Demirkan, Panayiotis Panayiotidis, Wojciech Jurczak, Pier Zinzani, Mary-Margaret Keating, Sung-Soo Yoon, Miklos Egyed, Constantine Tam, Nathalie Johnson, Edith Szafer-Glusman, Jennifer Lin, James Dean, Jutta Neuenburg, Gottfried von Keudell

June 1, 2025

Allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia adults in complete remission: A systematic review and meta-analysis.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies
Abstract #6559; Poster Bd #175
Muhammad Umair Mushtaq, Pramod Singh, Asad Zaman, Muhammad Abdullah Humayun, Abdul Rafae Faisal, Ali Shan, Hameer Ali, Muhammad Faizan, Waseh Ahsan, Arfa Ahmed, Rameesha Mehreen, Muhammad Ahmad Sadiq, Saba Sattar, Muhammad Kashif Amin, Joseph McGuirk, Moazzam Shahzad

Clinical outcomes of cytomegalovirus infection among patients receiving chimeric antigen receptor T cell therapy.
9:00 AM – 12:00 PM CDT

Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #7021; Poster Bd #204
Muhammad Atif Khan, Muhammad Shafiq, Mehran Khan, Faiza Humayun Khan, Zahra Mahmoudjafari, Chelsea Gorsline, Al-Ola Abdallah, Joseph McGuirk, Briha Ansari, Nausheen Ahmed

Factors associated with outcomes following reduced intensity conditioning haploidentical hematopoietic cell transplantation in acute myeloid leukemia.
9:00 AM – 12:00 PM CDT

Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies
Abstract #6560; Poster Bd #176
Muhammad Umair Mushtaq, Muhammad Kashif Amin, Amir Kasaeian, Iman Oskouie, Hediyeh Alemi, Naghmeh Khavandgar, Sibgha Chaudhary, Iqra Anwar, Joseph McGuirk, Moazzam Shahzad

Risk of second primary hematological malignancy post CAR-T cell therapy in relapsed/refractory multiple myeloma: Propensity-matched analysis using TriNetX database.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia
Track: Hematologic Malignancies
Abstract #7523; Poster Bd #91
Rushi Shah, Nikhil Vojjala, Deevyashali Parekh, Avi Harisingani, Adit Dharia, Rishab Prabhu, Shajadi Patan, Nausheen Ahmed

SynKIR-CAR T cell advanced research (STAR)-101 phase 1 clinical trial for patients with advanced mesothelin-expressing ovarian cancer, mesothelioma, or cholangiocarcinoma.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Gynecologic Cancer
Track: Gynecologic Cancer
Abstract #TPS5630; Poster Bd #522a
Janos Tanyi, Andrew Haas, Mark O'Hara, Mehmet Altan, Zhubin Gahvari, Raed Al-Rajabi, Daniel Sterman, Michael Milone, Susan Howard, Emily Winters, Andrea Campanile, Jun Xu, Laura Johnson

Comparative effectiveness of delivering early palliative care via video versus in-person on end-of-life outcomes in patients with advanced lung cancer.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Care Delivery/Models of Care
Track: Care Delivery and Quality Care
Abstract #1649; Poster Bd #415
Jessica Bauman, Areej El-Jawahri, Simone Rinaldi, Vicki Jackson, Emily Gallagher-Medeiros, Nora Horick, Dustin Rabideau, Jacob Strand, Finly Zachariah, Laura Shoemaker, Marie Bakitas, Lori Spoozak, Carl Grey, Kimberly Curseen, Eytan Szmuilowicz, Ramona Rhodes, Amelia Cullinan, Brianna Jewett, Jennifer Temel, Joseph Greer

Intervention adherence, engagement and tool utilization in the breast cancer weight loss (BWEL) trial by race and ethnicity (Alliance A011401).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Care Delivery/Models of Care
Track: Care Delivery and Quality Care
Abstract #1586; Poster Bd #352
Ashley Odai-Afotey, Linda McCall, Karla Ballman, Chao Cao, Pamela Goodwin, Vanessa Bernstein, Linda Delahanty, Dawn Hershman, Judith Hopkins, Erica Mayer, Electra Paskett, Patricia Spears, Vered Stearns, Anna Weiss, Julia White, Thomas Wadden, Eric Winer, Lisa Carey, Ann Partridge, Jennifer Ligibel

Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
11:21-11:27 AM CDT
S406 | On Demand
Rapid Oral Abstract Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #2513
Anup Kasi, Michael Birrer, Jason Brown, Sanjay Chandrasekaran, Vincent Chung, Richard Frank, Shirish Gadgeel, Thomas George, Shadia Jalal, Alberto Mendivil, Andrew Poklepovic, Jennifer Segar, Alexander Spira, Janos Tanyi, Hira Yousaf, Jillian Zhang, Xin-Yun Huang, Jose Jimeno, Frank Tsai

Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #7026; Poster Bd #209
Manali Kamdar, Mazyar Shadman, Sairah Ahmed, Jeremy Abramson, Miguel-Angel Perales, Nausheen Ahmed, Sayeef Mirza, Iris Isufi, Matthew Frigault, Jennifer Crombie, David Miklos, Alberto Vasconcelos, Alessandro Crotta, David Bernasconi, Debasmita Roy, Eric Bleickardt, Marcelo Pasquini, Bradley Hunter, Matthew Lunning

Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.
9:06-9:12 AM CDT
Hall B1 | Live Stream
Rapid Oral Abstract Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract #516
Kevin Kalinsky, Mattea Reinisch, Yen-Shen Lu, Marc Debled, Binghe Xu, Lowell Hart, Stephanie Graff, Qiang Liu, Michael Untch, Sherene Loi, Priyanka Sharma, Viktoriya Sakalosh, Melissa Gao, Elizabeth Santarsiero, Sorcha Waters, Shaheen Islam, Seock-Ah Im

Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Sessions
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #7024; Poster Bd #207
Narendranath Epperla, Babatunde Adedokun, Hamza Hashmi, Mazyar Shadman, Allison Winter, Alex Herrera, Mehdi Hamadani, Caron Jacobson, Nausheen Ahmed, Waleska Perez, Zhongyu Feng, Kenny Hu, Brad Du, Jenny Kim, Timothy Best, Anjani Baer, Arjana Pradhan, Marcelo Pasquini, Sairah Ahmed

Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.
12:12-12:18 PM CDT
Hall D1 | Live Stream
Rapid Oral Abstract Session
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Track: Gastrointestinal Cancer—Colorectal and Anal
Abstract #3517
Anwaar Saeed, Jun Zhang, Babar Bashir, Alexander Philipovskiy, Robert Lentz, Shira Amsili, Rinat Tabakman, Maria Marinova, Yaffa Shwartz, Adam Foley-Comer, Antonio Jimeno

Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV).
2:09-2:21 PM CDT
Hall B1 | Live Stream
Plenary Session
Session Title: Plenary Session
Track: Special Sessions
Abstract #LBA3
Andrew Kuykendall, Naveen Pemmaraju, Kristen Pettit, Joseph Shatzel, Alessandro Lucchesi, Valentin García-Gutierrez, Jiří Mayer, Abdulraheem Yacoub, Harinder Gill, Antonin Hlusi, Daniel Sasca, Joseph Scandura, Marina Kremyanskaya, Phil Dinh, Sarita Khanna, Suneel Gupta, Arturo Molina, Aniket Bankar

Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial.
Arie Crown Theater | Live Stream

5:18-5:13 PM CDT
Clinical Science Symposium
Session Title: The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: ctDNA for Breast Cancer: It's Here—Are We Ready?
Track: Breast Cancer
Abstract #1012
Shane Stecklein, William Barlow, Jill Tsai, Arielle Yablonovitch, Eve Rodler, Peter Kuhn, James Hicks, Harsh Pathak, Daniel Hayes, James Rae, Gabriel Hortobagyi, Alastair Thompson, Andrew Godwin, Lajos Pusztai, Priyanka Sharma

June 2, 2025

Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Metastatic
Track: Breast Cancer
Abstract #1094; Poster Bd #73
Priyanka Sharma, Jaimie Heldstab, Rachel Yoder, Joshua Staley, India Fernandez, Adam Heinrich, Chasity Cupp, Hope Owens, Brent Sear, Spencer Beaman, Scott Weir, Anne O'Dea, Andrew Godwin, Shane Stecklein, Qamar Khan

Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Metastatic
Track: Breast Cancer
Abstract #1091; Poster Bd #70
Nanuli Gvazava, Qamar Khan, Lauren Clark, Joaquina Baranda, Priyanka Sharma, Taylor Monson, Milind Phadnis, Colleen Bohnenkamp, Anne O'Dea, Manana Elia, Lauren Nye, Robert Pluenneke, Laura Mitchell, Raed Al-Rajabi, Mark Fesen, Stephanie LaFaver,Anup Kasi

Association of ImPrintTN signature with survival outcomes by race in basal-type triple negative breast cancer (TNBC): FLEX registry analysis.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract #554; Poster Bd #147
Priyanka Sharma, Shane Stecklein, Denise Wolf, Christina Yau, Laura Esserman, Laura van t Veer, David Page, Harshini Ramaswamy, Sahra Uygun, Josien Haan, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy

Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker based study (Alliance A032102).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Track: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract #TPS5114; Poster Bd #311a
Rana McKay, Glenn Heller, Shuang Zhao, Elizabeth Wulff-Burchfield, Dhaval Shah, Alan Tan, Matthew Galsky, Jonathan Rosenberg, Himisha Beltran

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract #TPS625; Poster Bd #213a
Julia White, Reena Cecchini, Eleanor Harris, Eleftherios Mamounas, Jose Bazan, Daniel Stover, Patricia Ganz, Reshma Jagsi, Stewart Anderson, Carmen Bergom, Valérie Théberge, Mahmoud El-Tamer, Richard Zellars, Dean Shumway, Guang-Pei Chen, Thomas Julian, Norman Wolmark

A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with osseous metastases (RADICAL/Alliance A031801).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Genitourinary Cancer—Kidney and Bladder
Track: Genitourinary Cancer—Kidney and Bladder
Abstract #TPS4616; Poster Bd #413b
Chinmay Jani, Heather Jacene, Pamela Atherton, Archana Ajmera, Tyler Zemla, Ronald Chen, Atish Choudhury, Joshua Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Alan Tan, Himisha Beltran, Michael Morris, Matthew Galsky, Jonathan Rosenberg, Daniel George, Toni Choueiri, Rana McKay

FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Head and Neck Cancer
Track: Head and Neck Cancer
Abstract #TPS6115; Poster Bd #520a
Julie Bauman, Lisa Licitra, Bhumsuk Keam, Jessica Bauman, Victor Lin, Neal Akhave, Jérôme Fayette, Prakash Neupane, Hussein Soudy, Byoung Chul Cho, Christine Chung, Nabil Saba, Deborah Wong, Kevin Harrington, Christophe Le Tourneau, Suzy Muggeo, Bo Jin, Claudia Lebedinsky, Edgar Braendle, Robert Haddad

Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Genitourinary Cancer—Kidney and Bladder
Track: Genitourinary Cancer—Kidney and Bladder
Abstract #4558; Poster Bd #358
Benjamin Maughan, Jesse Troy, Yousef Zakharia, Elizabeth Wulff-Burchfield, Nrupen Bhavsar, Yasser Ged, Ajjai Alva, Priyanka Chablani, Brian Costello, Deepak Kilari, Sorab Gupta, Melyssa Bratton, Muhammad Furqan, Tracy Rose, Sarah Jabusch, Kimberly Ward, Courtney Page, Daniel George, Tian Zhang, Michael Harrison

A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract #TPS615; Poster Bd #208a
Eleftherios Mamounas, Gong Tang, Shannon Puhalla, Sandra Swain, Patricia Ganz, Norah Henry, Reena Cecchini, Sonya Reid, Priya Rastogi, Charles Geyer Jr., Julia White, Amy Clark, Tufia Haddad, Gregory Vidal, Norman Wolmark

Association of lifestyle factors and pathological characteristics in patients with early breast cancer and overweight/obesity: Results from the Breast Cancer Weight Loss (BWEL) trial.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract #561; Poster Bd #154
Caterina Sposetti, Karla Ballman, Linda McCall, Pamela Goodwin, Anna Weiss, Cynthia Thomson, Olwen Hahn, Dawn Hershman, Electra Paskett, Lori Minasian, Linda Nebeling, Erica Mayer, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, Eric Winer, Ann Partridge, Lisa Carey, Jennifer Ligibel

A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title; Breast Cancer—Metastatic
Track: Breast Cancer
Abstract #TPS1120; Poster Bd #99a
Lior Braunstein, Melissa Mitchell, Hanna Bandos, William Sikov, Atif Khan, Peter Chen, Patricia Ganz, Reshma Jagsi, Julia White, Reena Cecchini, Hyejoo Kang, Shannon Puhalla, Kelly Bolton, Eileen Connolly, Erica Stringer-Reasor, Kimberly Gergelis, Thomas Julian, Eleftherios Mamounas, Norman Wolmark

Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Genitourinary Cancer—Kidney and Bladder
Track: Genitourinary Cancer—Kidney and Bladder
Abstract #4553; Poster Bd #353
Michael Harrison, Jesse Troy, Benjamin Maughan, Yousef Zakharia, Elizabeth Wulff-Burchfield, Nrupen Bhavsar, Yasser Ged, Ajjai Alva, Priyanka Chablani, Brian Costello, Deepak Kilari, Sorab Gupta, Melyssa Bratton, Muhammad Furqan, Tracy Rose, Sarah Jabusch, Kimberly Ward, Courtney Page, Tian Zhang, Daniel George

Estrogen receptor (ER) expression on circulating tumor cells (CTCs) and cell free DNA (cfDNA) mutational landscape in the PACE randomized phase II study.
9:00 AM – 12:00 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Breast Cancer—Metastatic
Track: Breast Cancer
Abstract #1054; Poster Bd #33
Carolina Reduzzi, Mara Serafini, Lorenzo Gerratana, Rinath Jeselsohn, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Jane Meisel, Kathy Miller, Yara Abdou, Elizabeth Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Yuan Liu, Yue Ren, Meredith Regan, Huiping Liu, Erica Mayer, Massimo Cristofanilli

Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia?

11:30 AM – 12:45 PM CDT
E450b | On Demand

Education Session
Session Title: Changes in Upfront Therapy in Hematologic Malignancies
Track: Hematologic Malignancies | Geriatric Oncology
Session Chair and Presenter: Tara L. Lin

Predictors and clinical outcomes of CMV reactivation in CAR-T therapy: A systematic review.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #2543; Poster Bd #190
Faiza Humayun Khan, Muhammad Atif Khan, Abat Khan, Pramod Singh, Abdul Rafae Faisal, Salman Sani, Abid Nawaz Khan Adil, Arslan Inayat, Briha Ansari, Nausheen Ahmed

A novel cellular immunotherapy using vaccine generated neoantigen-specific effector T cells.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #2537; Poster Bd #184
Andrew Sloan, Barry Skikne, Tolga Tuncer, Patrick Grogan, Navid Redjal, John Yu, Jean Aguiar, Gary Wood

Hepatotoxic adverse events with immune checkpoint inhibitors: Real world pharmacovigilance study using FAERS database.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #2602; Poster Bd #249
Panah Parab, Nikhil Vojjala, Charmi Bhanushali, Bibi Maryam, Rishab Prabhu, Shajadi Patan, Sharanya Tripathi, Nausheen Ahmed

Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #TPS3178; Poster Bd #482b
Shiraj Sen, Aram Hezel, Anup Kasi, Nehal Lakhani, Alexander Spira, Rajwanth Veluswamy, Chenming Xu, Hisaki Fujii, Stanley Gill, Ho-Jin Lee, William McKean

Effectiveness of the Automated Heart-Health Assessment (AH-HA) tool on cardiovascular health improvements among post-treatment cancer survivors: 12-month results from WF-1804CD.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Symptom Science and Palliative Care
Track: Symptom Science and Palliative Care
Abstract #12019; Poster Bd #9
Kathryn Weaver, Emily Dressler, Heidi Klepin, Sydney Smith, Chandylen Nightingale, Stephanie Sohl, Simon Lee, Brian Wells, William Hundley, Randi Foraker

Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #3039; Poster Bd #354
Ira Winer, Noelle Cloven, Debra Richardson, Lyndsay Willmott, Justin Call, Jessica Thomes Pepin, Gottfried Konecny, Andrea Jewell, Cara Mathews, Leigh Seamon, Joseph Buscema, Nurgul Kilavuz, Michael Gillespie, Ibrahima Soumaoro, Elizabeth Lee

Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #2572; Poster Bd #219
Aung Naing, Khaldoun Almhanna, Joaquina Baranda, Vladimir Galvao, Elena Garralda, Emiliano Calvo, Marloes Dongen, Ferry Eskens, Jonathan Cohen, Tamar Beller, Fatima Menas, Chen Zhu, Keisuke Tada, Helene Guillemin-Paveau, Victorine Koch, Winston Huh, Giovanni Abbadessa, Raymond Perez, Martin Gutierrez

A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3087; Poster Bd #402
Philippos Costa, Mary Josephine Pilat, Jordi Rodon Ahnert, Melissa Burgess, Gabriel Tinoco, Julia Close, Roman Groisberg, Vivek Subbiah, Benjamin Powers, Candace Haddox, Juneko Grilley-Olson, Vicki Keedy, Jing Li, S. Ivy, Abhijit Patel, Geoffrey Shapiro, Jeffrey Ishizuka, Kurt Schalper, Patricia LoRusso

Radioimmunotherapy-associated myeloid neoplasms: Real-world multicenter retrospective study using TriNetX database.
1:30 PM – 4:30 PM CDT
Hall A - Posters and Exhibits | On Demand
Poster Session
Session Title: Symptom Science and Palliative Care
Track: Symptom Science and Palliative Care
Abstract #12043; Poster Bd #63
Nikhil Vojjala, Deevyashali Parekh, Avi Harisingani, Jayalekshmi Jayakumar, Rishab Prabhu, Shajadi Patan, Nausheen Ahmed, Vijendra Singh

June 3, 2025

ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
11:09-11:21 AM CDT
Hall D1 | Live Stream
Oral Abstract Session
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Track: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract #5005
Andrew Armstrong, Daniel Petrylak, Neal Shore, Russell Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Ruslan Croitoru, Ruishan Wu, Matko Kalac, Yiyun Tang, Arnulf Stenzl, Arun Azad

Publication Only

Thrombotic events and mortality associated with bispecific antibodies in lung cancer: A systematic review.
Session Title: Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #e15101
Ahmad Basharat, Saeed Aftab Khan, Aman Ullah, Zeeshan Sattar, Valiko Begiashvili, Muhammad Kashif Amin, Sarmad Warraich, Iqra Anwar, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Fatima Tuz Zahra, Michael Jaglal, Moazzam Shahzad

Impact of KRAS mutation status on outcomes in peritoneal metastatic mucinous adenocarcinoma of the colon and appendix following CRS-HIPEC: A retrospective analysis.
Session Title: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
Track: Gastrointestinal Cancer—Colorectal and Anal
Abstract #e15578
Sanjana Mullangi, Manidhar Reddy Lekkala, Aubrey Swilling, Jill Haley, Weijing Sun, Raed Al-Rajabi, Joaquina Baranda, Haoran Li, Luke Selby, Shahid Umar, Mazin Al-Kasspooles, Anup Kasi

Real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in HER2-overexpressing malignancies: A single-center retrospective study.
Session Title: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
Track: Gastrointestinal Cancer—Colorectal and Anal
Abstract #e15577
Sunny Cai, Kirstin Binz, Sanjana Mullangi, Nahid Suleman, Anup Kasi, Jun Zhang, Raed Al-Rajabi, Chao Huang, Prakash Neupane, Weijing Sun, Haoran Li

Missing data and missed opportunities: Inability to perform secondary analysis of prospective randomized control trials due to missing general anesthesia data.
Session Title: Publication Only: Quality Care/Health Services Research
Track: Care Delivery and Quality Care
Abstract #e23012
Aubrey Swilling, Mazin Al-Kasspooles, Anup Kasi, Gary Doolittle, Erin Plaza, Luke Selby

Real-world safety and efficacy of tarlatamab in patients with small cell lung cancer or extrapulmonary small cell carcinoma.
Session Title: Publication Only: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track: Lung Cancer
Abstract #e20127
Sanjana Mullangi, Manidhar Reddy Lekkala, Sarah Blocker, Diana Kim,Jun Zhang,Chao Huang,Prakash Neupane, Haoran Li, Timothy Schieber

Associations of age, frailty status, and comorbidity status with post-operative outcomes following CRS-HIPEC.
Session Title: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #e16060
Kaylee Gleason, Mazin Al-Kasspooles, Hayrettin Okut, Jill Haley, Brian Dean

Neurologic adverse effects associated with the use of T-cell engager therapy in multiple myeloma: Insights from FAERS database.
Session Title: Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia
Track: Hematologic Malignancies
Abstract #e19502
Faiza Humayun Khan, Muhammad Atif Khan, Zahra Mahmoudjafari, Al-Ola Abdallah, Joseph McGuirk, Briha Ansari, Nausheen Ahmed

Outcomes with targeted therapy for NRAS-mutated melanoma: A systematic review and meta-analysis.
Session Title: Publication Only: Melanoma/Skin Cancers
Track: Melanoma/Skin Cancers
Abstract #e21506
Abat Khan, Nouman Aziz, Umar Akram, Muhammad Kashif Amin, Valiko Begiashvili, Sarmad Warraich, Iqra Anwar, Muhammad Umair Mushtaq, Robin Park, Michael Jaglal, Moazzam Shahzad

Outcomes with nivolumab maintenance after autologous hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
Session Title: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #e19037
Parisa Aijaz, Ahmad Basharat, Umar Akram, Zeeshan Sattar, Abat Khan, Muhammad Kashif Amin, Sarmad Warraich, Iqra Anwar, Fatima Tuz Zahra, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Intravenous vitamin C as an adjunct to standard therapy in pancreatic ductal adenocarcinoma: A systematic review of clinical trials.
Session Title: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #e16396
Waleed Mir, Abat Khan, Muhammad Kashif Amin, Sarmad Warraich, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Tarlatamab-induced immune-related adverse events: Retrospective real-world pharmacovigilance study using FAERS database.
Session Title: Publication Only: Symptom Science and Palliative Care
Track: Symptom Science and Palliative Care
Abstract #e24106
Nikhil Vojjala, Jayalekshmi Jayakumar, Charmi Bhanushali, Rishab Prabhu, Akshit Chitkara, Jasmeet Kaur, Moazzam Shahzad, Ibrahim Azar, Forat Lutfi, Zahra Mahmoudjafari, Muhammad Atif Khan, Joseph McGuirk, Prakash Neupane, Nausheen Ahmed

Efficacy and safety of CDK4/6 inhibitors in HER2-positive breast cancer: A systematic review and meta-analysis.
Session Title: Publication Only: Breast Cancer—Metastatic
Track: Breast Cancer
Abstract #e13013
Ammad Naeem, Waleed Mir, Muhammad Kashif Amin, Saeed Aftab Khan, Sarmad Warraich, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Outcomes of KRAS G12C inhibitors in metastatic pancreatic cancer: A systematic review and meta-analysis.
Session Title: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #e16206
Jawad Noor, Muhammad Fareed Khalid, Maheen Zahid, Shiza Khan, Sarmad Warraich, Muhammad Kashif Amin, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Outcomes with KRAS G12C inhibitors in metastatic non-small cell cancer: A systematic review and meta-analysis.
Session Title: Publication Only: Lung Cancer—Non-Small Cell Metastatic
Track: Lung Cancer
Abstract #e20647
Sarmad Warraich, Jawad Noor, Muhammad Fareed Khalid, Shiza Khan, Maheen Zahid, Muhammad Kashif Amin, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Outcomes with KRAS G12C inhibitors in metastatic colorectal cancer: A systematic review and meta-analysis.

Session Title: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
Track: Gastrointestinal Cancer—Colorectal and Anal
Abstract #e15544
Muhammad Fareed Khalid, Shiza Khan, Maheen Zahid, Jawad Noor, Sarmad Warraich, Muhammad Kashif Amin, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Impact of liquid biopsy on health-related quality of life in cancer treatment: A systematic review.
Session Title: Publication Only: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #e14538
Muhammad Kashif Amin, Nouman Aziz, Syed Maaz Tariq, Robin Park, Michael Jaglal, Muhammad Umair Mushtaq, Moazzam Shahzad

Role of high-dose vitamin C as adjunct treatment in gastric and colorectal cancers: A systematic review.
Session Title: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
Track: Gastrointestinal Cancer—Colorectal and Anal
Abstract #e15567
Sarmad Warraich, Hafiz Muhammad Hannan Javed, Pramod Singh, Qamar Iqbal, Muhammad Kashif Amin, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Outcomes with non-BCMA CAR T cell therapy for multiple myeloma: A systematic review and meta-analysis.
Session Title: Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia
Track: Hematologic Malignancies
Abstract #e19541
Syed Maaz Tariq, Muhammad Fareed Khalid, Jawad Noor, Ibrahim Khamees, Sarmad Warraich, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Outcomes of odronextamab in non-Hodgkin lymphoma: A systematic review and meta-analysis.
Session Title: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract #e19006
Syed Maaz Tariq, Muhammad Fareed Khalid, Jawad Noor, Ibrahim Khamees, Sarmad Warraich, Muhammad Salman Faisal, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Mortality and readmission rates post CAR-T cell therapy in relapsed/refractory multiple myeloma: Real-world, multicentre, retrospective cohort study using TriNetX database.
Session Title: Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia
Track: Hematologic Malignancies
Abstract #e19564
Kanika Goyal, Nikhil Vojjala, Deevyashali Parekh, Avi Harisingani, Adit Dharia, Rishab Prabhu, Srijan Valasapalli, Shajadi Patan, Joseph McGuirk, Nausheen Ahmed

Efficacy of peptide receptor radionuclide therapy in combination with capecitabine and temozolomide in neuroendocrine tumors: A systematic review and meta-analysis.
Session Title: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #e16345
Hafiz Muhammad Hannan Javed, Qamar Iqbal, Muhammad Kashif Amin, Amir Kasaeian, Hediyeh Alemi, Iman Oskouie, Sarmad Warraich, Iqra Anwar, Turab Muhammad, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Incident reporting and outcomes of gastrointestinal adverse events with immune checkpoint inhibitors.
Session Title: Publication Only: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #e14663
Nikhil Kumar Kotla, Charmi Bhanushali, Nikhil Vojjala, Supriya Peshin, Kanika Goyal, Rushi Shah, Rishab Prabhu, Srijan Valasapalli, Shajadi Patan, Nausheen Ahmed

Outcomes of ipilimumab plus nivolumab in metastatic merkel cell carcinoma: A systematic review and meta-analysis.
Session Title: Publication Only: Melanoma/Skin Cancers
Track: Melanoma/Skin Cancers
Abstract #e21586
Aminah Tayyab, Muhammad Fareed Khalid, Aniqa Faraz, Saeed Khan, Ahmad Basharat, Sarmad Warraich, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis.
Session Title: Publication Only: Sarcoma
Track: Sarcoma
Abstract #e23518
Sandeep Guntuku, Sripada Preetham Kasire, Krishna Doshi, Nandhini Iyer, Laxman Yashwant Byreddi, Sugam Gouli, Ravi Paluri, Ashish Manne, Anup Kasi

Outcomes with imetelstat in myelofibrosis: A systematic review and meta-analysis.
Session Title: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies
Abstract #e18593
Hafiz Muhammad Hannan Javed, Qamar Iqbal, Pramod Singh, Muhammad Fareed Khalid, Sarmad Warraich, Iqra Anwar, Muhammad Umair Mushtaq, Michael Jaglal, Moazzam Shahzad

Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML).
Session Title: Publication Only: Pediatric Oncology
Track: Pediatric Oncology
Abstract #: e22007
Robin Williams, Lane Miller, Stephanie Massaro, Elizabeth Krieger, Melinda Pauly, Catherine Nelson, Rebecca Johnson, Jennifer Welch, Deepa Bhojwani, Babak Moghimi, Philip Neff, Terzah Horton, Hamayun Imran, Raul Ribeiro, Terri Guinipero, Felipe Bautista, Matthew Kutny, Amy Johnson, Karen Lewing, Soheil Meshinchi

Hematology-oncology education in postgraduate internal medicine programs in Nepal: Current status and the pressing need for improvement.
Session Title: Publication Only: Medical Education and Professional Development
Track: Medical Education and Professional Development
Abstract #e21020
Ramila Shilpakar, Bibek Acharya, Prakash Neupane, Bishnu Paudel, Sandhya Acharya, Bishal Paudel, Anuj K.C., Rajeev Sharma, Shama Pandey, Pradeep Thapa, Lokendra Kunwar, Bishesh Sharma Poudyal

Serum MUC5AC as a dynamic biomarker for tumor response, prognosis, and risk stratification in resected pancreatic ductal adenocarcinoma.
Session Title: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract #e16364
Ashish Manne, Deepak Sherpally, Ravi Paluri, Anup Kasi, Kannan Thanikachalam, Ashwini Esnakula

Comparative efficacy and safety of CAR T-cell therapy versus standard of care for relapsed/refractory diffuse large B-cell lymphoma: A meta-analysis.
Session Title: Publication Only: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract #e14526
Nneoma Ubah, Suchith Boodgere Suresh, Muhammad Wazir, Chidiebube Ugwu, Eugene Annor, Gogo Ibodeng, Anup Kasi

Pathogenic germline variants in breast cancer patients associated with different HER2 expression levels.
Session Title: Publication Only: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract #e12543
Ning Liao, Jiayan Wu, Guochun Zhang, Jeffrey N Weitzel, Armando Giuliano, Charles Balch

Novel MAML2 fusions as oncogenic drivers in human malignancy.
Session Title: Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #e15067
Takefumi Komiya, Kieran Sweeney, Chao Huang, Anthony Crymes, Beverly Wang, Emmanuel Antonarakis, Andrew Elliott, Matthew Oberley, Mark Evans

April 27, 2025

APOBEC4, a novel regulator of p53-dependent cell cycle arrest, senescence, and apoptosis

Session Title: Mechanisms of Oncogenesis and Tumor Suppression

Session Type: Poster Session

Location: Section 11

Time: 2 - 5 PM  

Number: 262

Dipesh Thapa, Atul Ranjan, Elizabeth Thoenen, Alejandro Parrales, Shigeto Nishikawa, Jay Vivian, Tomoo Iwakuma

Deciphering the biology of colorectal metastasis to the peritoneal surface

Session Title: Spatial Proteomics and Transcriptomics 1

Session Type: Poster Session

Location: Section 32

Time: 2 - 5 PM  

Number: 774

Shahid Umar, Badal C. Roy, Amrita Mitra, Jill Haley, Harsh B. Pathak, Andrew K. Godwin, Luke V. Selby, Mazin Al-Kasspooles

Clec4f is expressed in a subset of PDAC metaplastic neuroendocrine cells and alters tumor cell growth

Session Title: Growth Factors, Receptors, and GTPase Signaling

Session Type: Poster Session

Location: Section 10

Time: 2 - 5 PM  

Number: 241

Bailey A. Bye, R. McKinnon Walsh, Austin E. Eades, Kathleen E. DelGiorno, Michael N. VanSaun

RUNDC1 is required for p53-mediated tumor suppression

Session Title: Mechanisms of Oncogenesis and Tumor Suppression

Session Type: Poster Session

Location: Section 258

Time: 2 - 5 PM  

Number: 258

Atul Ranjan, Elizabeth Thoenen, Mrinalini Bhosale, Dipesh Thapa, Alejandro Parrales, Tomoo Iwakuma

Differences in gene expression across races in pediatric T-cell acute lymphoblastic leukemia (T-ALL)

Session Title: Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes

Session Type: Poster Session

Location: Section 22

Time: 2 - 5 PM  

Number: 505

Rishabh Gaur, Irina Pushel, Midhat Farooqi

Piloting NTRK fusion-specific oncogenicity guidelines - lessons learned

Session Title: Database Resources

Session Type: Poster Session

Location: Section 46

Time: 2 - 5 PM  

Number: 1075

Jason Saliba, Shivani Golem, Arpad Danos, Laura B. Corson, Elan Hahn, Morteza Seifi, Emma G. Sullivan, Jan Clement A. Santiago, Valentina Nardi, Theodore W. Laetsch, Marilyn M. Li, Obi L. Griffith, Malachi Griffith, Gordana Raca, Larissa V. Furtado, Alanna J. Church, Angshumoy Roy

April 28, 2025

Disrupting ER-AR crosstalk using AR degraders: a novel approach to treating endocrine resistant breast cancer

Session Title: Drug Resistance in Molecular Targeted Therapies 2

Session Type: Poster Session

Location: Section 20

Time: 9 AM - 12 PM  

Number: 1713

Matt Konda, Obdulia Covarrubias-Zambrano, Stefan H. Bossmann, Joan Lewis-Wambi

Therapeutic implication of pH/hypoxic responsive nanoencapsulated tunicamycin on pancreatic cancer by targeting K-Ras^G12D

Session Title: Drug Delivery

Session Type: Poster Session

Location: Section 25

Time: 9 AM - 12 PM  

Number: 1843

Axel H. Breier, Debasmita Dutta, Anjali Kambhampati, Inamul Haque, Archana De, Sunil P. Upadhyay, Sushanta K. Banerjee, Mohiuddin Quadir, Snigdha Banerjee

Investigation of early dissemination in ductal carcinoma in situ patients using circulating tumor cells

Session Title: Diagnostic Biomarkers 3: Early Detection Biomarkers

Session Type: Poster Session

Location: Section 27

Time: 9 AM - 12 PM  

Number: 1918

Neha Nagpal, Brittany Rupp, Yan Hong, Fariba Behbod, Max Wicha, Sunitha Nagrath

DNA methylation-estimated C-reactive protein levels and lung cancer risk and mortality in individuals with a heavy smoking history

Session Title: Advancing Genomic and Epigenetic Insights in Cancer Across Diverse Populations: Genetics, Genomics, and Epigenetics

Session Type: Poster Session

Location: Section 39

Time: 9 AM - 12 PM  

Number: 2263

Laurie Grieshober, Stefan Graw, Matt J. Barnett, Gary E. Goodman, Chu Chen, Devin C. Koestler, Carmen J. Marsit, Jennifer A. Doherty. H

Genetic architecture of breast cancer across diverse populations: Assessing heritability, genetic correlation, and polygenicity

Session Title: Advancing Genomic and Epigenetic Insights in Cancer Across Diverse Populations: Genetics, Genomics, and Epigenetics

Session Type: Poster Session

Location: Section 39

Time: 9 AM - 12 PM  

Number: 2282

James L. Li, Maria Zanti, Jacob Williams, Om Jahagirdar, Guochong Jia, Qiang Hu, Jean-Tristan Brandenburg, Li Yan, Weang-Kee Ho, Jingmei Li, José P. Miranda, Devika Godbole, Julie-Alexia Dias, Leila Dorling, Wenlong C. Chen, Nicholas Boddicker, Ying Wang, Alicia Martin, Martin J. Zhang, Yan Zhang, Joe Dennis, Esther M. John, Gabriela Torres-Mejia, Larry Kushi, Jeffrey Weitzel, Susan L. Neuhausen, Luis Carvajal-Carmona, Christopher Haiman, Elad Ziv, Laura Fejerman, Wei Zheng, Dezheng Huo, Douglas Easton, Nilanjan Chatterjee, Peter Kraft, Montserrat Garcia-Closas, Wendy Wong, Kyriaki Michailidou, Qianqian Zhu, Diptavo Dutta, Thomas U. Ahearn, Haoyu Zhang

Multi-omic profiling reveals subtype-specific signaling mechanisms in pediatric B-cell acute lymphoblastic leukemias

Session Title: Developmental Origins and Drivers of Pediatric Cancers

Session Type: Poster Session

Location: Section 4

Time: 2 - 5 PM  

Number: 2607  

Irina Pushel, Zachary Clark, Michaella J. Rekowski, Lisa A. Lansdon, Byunggil Yoo, Keith J. August, Alan S. Gamis, Nicole M. Wood, Michael P. Washburn, Midhat S. Farooqi 

A tool for genome-wide induction of 8-oxo-guanine to study DNA biology and genome stability

Session Title: Origins and Mechanisms of Genomic Instability

Session Type: Poster Session

Location: Section 14

Time: 2 - 5 PM  

Number: 2841

Aninda S. Dey, Natalia Cestari Moreno, Ryan P. Barnes

Essential roles of CRK and CRKL in glioblastoma cell migration and invasion

Session Title: Invasion and Migration

Session Type: Poster Session

Location: Section 5

Time: 2 - 5 PM  

Number: 2647

Piyanka Hettiarachchi, Neka Large, Taeju Park

High-throughput identification of radiosensitizers and synergistic drug combinations with potent therapeutic efficacy against diffuse midline glioma

Session Title: High-Throughput Screening Assays and Libraries

Session Type: Poster Session

Location: Section 25

Time: 2 - 5 PM  

Number: 3153

Syed M. Faisal, Monika Yadav, Garrett R. Gibson, Adora T. Klinestiver, Ryan Sorenson, Anuradha Roy, Carl Koschmann, Scott J. Weir, Stefan H. Bossmann, Viveka N. Yadav

Radiomic features associated with anti-tumor activity in Non-Hodgkin lymphoma patients treated with CD19 directed allogenic CAR T therapy

Session Title: Adoptive Cell Therapy 1

Session Type: Poster Session

Location: Section 27

Time: 2 - 5 PM  

Number: 3199

Andrew R. Dunn, Shashwat Deepali Nagar, Donald J. Kirsch, Leah M. Williams, Annie Y. Weaver, Philipp M. Altrock, William S. Denney, Chan Y. Cheah, P. Joy Ho, Joseph P. McGuirk, Paul Shaughnessy, Constantine S. Tam, Armin Ghobadi

Exploiting PEGylation of CCN5 for tumor immunity and therapy of triple-negative breast cancer: A new and effective approach for TNBC therapy

Session Title: Modifiers of the Tumor Microenvironment

Session Type: Poster Session

Location: Section 30

Time: 2 - 5 PM  

Number: 3293

Sunil P. Upadhyay, Axel H. Breier, Inamul Haque, Archana De, Snigdha Banerjee, Mohiuddin Quadir, Sushanta K. Banerjee

Preliminary report of the TUMORIN Trial (using ex vivo tumoroids to predict immunotherapy response in NSCLC)

Session Title: Phase II and Phase III Clinical Trials

Session Type: Poster Session

Location: Section 50

Time: 2 - 5 PM  

Number: CT098

Jared Ehrhar, Seth Currlin, Michelle Attaya, Jun Zhang, Rikhia Chakraborty

Mitotic activities of Ewing sarcoma proteins

Session Title: Developmental Origins and Drivers of Pediatric Cancers

Session Type: Poster Session

Location: Section 4

Time: 2 - 5 PM  

Number: 2621

Evan Schulz, Mizuki Azuma

Therapeutic advances for high-risk and steroid-refractory aGvHD: Promising results from the phase 1b study of MSCTC-0010 Wharton's jelly mesenchymal stem cells (WJMSC)

Session Title: First-in-Human Phase I Clinical Trials 1

Session Type: Poster Session

Location: Section 49

Time: 2 - 5 PM  

Number: CT066

William C. Wesson, Jianzheng Wu, Milind Phadnis, Scott Weir, Tyce Bruns, Haitham Abdelhakim, Rupal Soder, Ramesh Balusu, Sunil Abhyankar, Joseph P. McGuirk

Innovative Approaches in Drug Discovery: Novel Leads, Degraders, and AI-Driven Solutions

Session Type: Minisymposium

Location: Room S100 (Grand Ballroom A) - McCormick Place South (Level 1)

Time: 2:30 - 4:30 PM  

Introduction: Joaquina Celebre Baranda

April 29, 2025

Elucidating the mechanisms of 2-deoxy-D-glucose (2-DG) and 2-deoxy-D-glucose phoaphate (2-DG-P) in maintaining gastrointestinal homeostasis

Session Title: Radiation Sciences 1

Session Type: Poster Session

Location: Section 33

Time: 9 AM - 12 PM  

Number: 4682

Rao V. Papineni, Shahid Umar, Prashanthi Karyala, Kavya Ramesh

Pathway-based analysis of genomic alterations in infant ALL

Session Title: Late-Breaking Research: Population Sciences

Session Type: Late-Breaking Poster Session

Location: Section 54

Time: 9 AM - 12 PM  

Number: LB329

Byunggil Yoo, Erin Guest, Midhat S. Farooqi

Haplotype-specific copy number profiling from long reads sequencing data

Session Title: Sequence Analysis and Genome Landscapes

Session Type: Poster Session

Location: Section 46

Time: 9 AM - 12 PM  

Number: 5049

Tanveer Ahmad, Mikhail Kolmogorov, Ayse Keskus, Ataberk Ataberk Donmez, Midhat Farooqi

Understanding clinician level barriers and facilitators to managing cancer survivors with chronic conditions at community health centers

Session Title: Cancer Survivorship and Patient Communication / Patient Advocacy and Engagement

Session Type: Poster Session

Location: Section 8

Time: 9 AM - 12 PM  

Number: 4016

Maram Museitif, Bijal Balasubramanian, Gretchen H. Walton, Laura Aubree Shay, Hilary Ma, Simon Lee

Dynamic proteomic biomarkers of survival outcomes with anti-PD-1 immunotherapy in head and neck squamous cell carcinoma

Session Title: Immune Response to Therapies

Session Type: Poster Session

Location: Section 28

Time: 2 - 5 PM  

Number: 5795

Md Saiful Islam Sai, Kartik Sehgal, Ze Zhang, Rondi Butler, John Wiencke, Annette Molinaro, Juliana Miller, Hannah Stolrow, Keisuke Shirai, Lucas Salas, Devin Koestler, Robert Haddad, Brock C. Christensen, Karl Kelsey

SPHK2 modulates the tumor-intrinsic response to STING agonism in triple-negative breast cancer cells

Session Title: Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 2

Session Type: Poster Session

Location: Section 40

Time: 2 - 5 PM  

Number: 6170

Colette R. Worcester, Shane R. Stecklein

Nuclear APC maintains colon homeostasis and mitigates inflammation

Session Title: Shaping Tumor Stromal Interactions in Cancer

Session Type: Poster Session

Location: Section 5

Time: 2 - 5 PM  

Number: 5214

Anika James, Kristi Neufeld

Blood DNA methylation in association with immune checkpoint inhibitor related outcomes among patients with head and neck squamous cell carcinoma

Session Title: Epigenetic Regulation and Its Impact on Drug Response, Disease Pathogenesis, and Outcomes Across Pediatric and Adult Cancers

Session Type: Minisymposium 

Location: Room E350 - McCormick Lakeside Center (Level 3)

Time: 2:30 - 4:30 PM  

Number: 6410

Gyeyoon Yim, Lucas Salas, Kartik Sehgal, Keisuke Shirai, Rondi Butler, Julianna Miller, Hannah Stolrow, Md Saiful Islam Saif, Devin Koestler, John Wiencke, Robert Haddad, Karl Kelsey, Brock Christensen

April 30, 2025

Novel ferrocene and naphthalene-based analogs block HRH1-signaling to inhibit colon cancer growth

Session Title: Novel Targets and Pathways

Session Type: Poster Session

Location: Section 23

Time: 9 AM - 12 PM  

Number: 6927

Affan Ahmad Ansari, Dileepkumar Veeragoni, Ahraar Azaz, Sangita Bhattacharya, Hindole Ghosh, Bernhard Biersack, Prasad Dandawate

Progesterone signaling alters the metabolic profile and immune cell landscape of mammary gland tumors

Session Title: The Soil Matters: Tumor Microenvironment Complexity and Targeting

Session Type: Poster Session

Location: Section 5

Time: 9 AM - 12 PM  

Number: 6543

Eilidh I. Chowanec, Christy R. Hagan, Jason Gertz

Intrauterine device use and ovarian cancer risk among 11 case-control studies and 7 prospective cohort studies

Session Title: Socioeconomic, Lifestyle, and Biological Drivers of Cancer Risk and Survival: Clinical Outcomes and Treatment Guidelines

Session Type: Poster Session

Location: Section 42

Time: 9 AM - 12 PM  

Number: 7377

Jennifer M. Mongiovi, Ana Babic, Allison F. Vitonis, Naoko Sasamoto, Mark K. Townsend, Brett M. Reid, Mollie E. Barnard, Holly R. Harris, Lauren Peres, Britton Trabet, Brooke L. Fridley, Katie M. O'Brien, Anita Koushik, Renee Turzanski Fortner, Jennifer A. Doherty, Joelle M. Schildkraut, Shelley S. Tworoger, Kathryn L. Terr

December 6, 2024

Addressing Current Questions and Controversies in the Management of Myelofibrosis - What Clinicians Want to Know

Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways: Education, Diseases
Time: 11 AM - 2 PM
Location: Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
Speakers: Abdulraheem Yacoub, MD, University of Kansas Cancer Center, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center and Angela G. Fleischman, MD, PhD, University of California, Irvine

December 7, 2024

December 9, 2024

772 | Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Time: 11:15 AM
Location: Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Vania Hungria, MD, PhD, Pawel Robak, MD, PhD, Marek Hus, MD, PhD, Vera Zherebtsova, MD, Christopher Ward, MD, PhD, Phoebe Joy Ho, MBBS, Roman Hajek, MD, PhD, Kihyun Kim, MD, Sebastian Grosicki, MD, PhD, Hanlon Sia, MBBS FRACP FRCPA, Adam Bryant, MBBS(Hon), PhD, FRACP, FRCPA, Marcelo Pitombeira de Lacerda, MD, PhD, Gracia Aparecida Martinez, MD, PhD, Anna Maria Sureda Balarì, MD, PhD, Irwindeep Sandhu, MD, Claudio Cerchione, MD, Peter Ganly, BMBCh, PhD, Meletios Dimopoulos, MD, Chengcheng Fu, Mamta Garg, MD, Al-Ola Abdallah, MD, Moshe E Gatt, MD, Albert Oriol, MD, Michele Cavo, MD, Robert Rifkin, MD, FACP, Tomoaki Fujisaki, MD, PhD, MichaÅ‚ Mielnik, MD, Nick Pirooz, MHA, Joe Lee, PhD, Astrid McKeown, PhD, Rachel Rogers, MS, Hena Baig, BS, Lydia Eccersley, MBBS, MRCP, FRCPath, PhD, Sumita Roy-Ghanta, MD and Maria Victoria Mateos, MD, PhD 
 
779 | Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant
Program: Oral and Poster Abstracts
Type: Oral
Time: 11:30 AM
Location: Room 6A (San Diego Convention Center)
Michaela Liedtke, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Ryan J Mattison, MD, Elisabeth Paietta, PhD, Kathryn G. Roberts, Yanming Zhang, MD, Janis Racevskis, PhD, Hillard M. Lazarus, MD, Jacob M. Rowe, MD, Daniel A. Arber, MD, Julie Bergeron, MD, Brent L. Wood, MD, PhD, Yaqi Zhao, MSc, Gang Wu, PhD, Ti-Cheng Chang, PhD, Wenchao Zhang, PhD, Keith W. Pratz, MD, Shira N. Dinner, MD, Noelle Frey, MD, MS, Steven D. Gore, MD, Bhavana Bhatnagar, DO, Ehab L. Atallah, MD, Geoffrey L. Uy, MD, Deepa Jeyakumar, MD, Tara L. Lin, MD, Cheryl L. Willman, MD, Daniel J. DeAngelo, MD, PhD, Shejal B. Patel, DO, Michelle A Elliott, MD, Anjali S. Advani, MD, Dimitrios Tzachanis, MD, PhD, Pankit Vachhani, MD, Rupali Bhave, MD, Elad Sharon, MD, MPH, Richard F. Little, MD, MPH, Harry P. Erba, MD, PhD, Richard M. Stone, MD, Selina Luger, MD, FRCPC, Charles G. Mullighan, MBBS, MSc, MD, Martin S. Tallman, MD and Matthew J. Wieduwilt, MD 
 
5044 | Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
Session: ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by Blood Global Hematology 
Program: ASH Poster Walks
Time: 12:30 - 1:30 PM
Location: Halls G-H - Blood Journals Studio (San Diego Convention Center)
Marie Michele Sainvil, MD, Melissa Lowe, MS, Delaney Underwood, MS, Yan Li, PhD, Tomi F. Akinyemiju, PhD, MS., Taewoong Choi, MD, Cristina Gasparetto, MD, Mitchell Horwitz, MD, Gwynn D. Long, MD, Richard Lopez, MD, Stefanie Sarantopoulos, MD, PhD, Edwin Alyea III, MD, Nelson J. Chao, MD, Thomas W. LeBlanc, MD, MA, MS, Yubin Kang, MD, Suzanne Kirby, MD, PhD, Chenyu Lin, MD, Matthew Stuart McKinney, MD, Alexandra Stefanovic, MD, Jie Wang, MD, MS, Andrea Sitlinger, MD, Sendhilnathan Ramalingam, MD, Anthony D. Sung, MD and Sanghee Hong, MD 
 
934 | Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
Session: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies
Program: Oral and Poster Abstracts
Type: Oral
Time: 3:30 PM
Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Oren Pasvolsky, MD, Danai Dima, MD, Lei Feng, MS, Wenli Dong, Tiffany Richards, PhD, NP, James A Davis, PharmD, Aimaz Afrough, Mariola A Vazquez-Martinez, MD, Aishwarya Sannareddy, MBBS, Utkarsh Goel, MBBS, Rahul Banerjee, MD, FACP, Jack Khouri, MD, Frances N. Cervoni Curet, MD, Mahmoud R. Gaballa, MD, Alex Lieberman-Cribbin, Masooma S Rana, MBBS, Kelley Julian, PharmD, Christopher J Ferreri, MD, Leyla O. Shune, MD, Shaun DeJarnette, Evguenia Ouchveridze, MD, Sandra Susanibar-Adaniya, MD, Andrew J. Portuguese, Hitomi Hosoya, MD, PhD, Lekha Mikkilineni, MD, MA, Gurbakhash Kaur, MD, MA, Adriana Rossi, MD, MSc, Megan M Herr, PhD, Daniel Schrum, PharmD, Chenyu Lin, MD, Shahzad Raza, MD, Yi Lin, MD, PhD, Shebli Atrash, MD, Joseph P. McGuirk, DO, Douglas W Sborov, MD, Peter M. Voorhees, MD, Faiz Anwer, MD, Melissa Alsina, MD, Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP, Alfred L. Garfall, MD, Surbhi Sidana, MD, Andrew J. Cowan, MD, Larry D Anderson Jr., MD, PhD, Doris K. Hansen, MD, Shambavi Richard, MD, Krina K. Patel, MD, MSc, Hans C. Lee, MD and Ariel Grajales-Cruz 
 
935 | Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkins Lymphoma
Session: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies
Program: Oral and Poster Abstracts
Type: Oral
Time: 3:45 PM
Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Jordan Snyder, PharmD, Dennis Grauer, MBA, Nausheen Ahmed, MD, Al-Ola Abdallah, MD, Marc Hoffmann, MD and Zahra Mahmoudjafari, PharmD
 
936 | Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
Session: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies
Program: Oral and Poster Abstracts
Type: Oral
Time: 4 PM 
Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Doris K. Hansen, MD, Lauren C. Peres, PhD, MPH, Danai Dima, MD, Alicia Richards, PhD, Leyla O. Shune, MD, Aimaz Afrough, MD, Shonali Midha, MD, Binod Dhakal, MBBS, Mehmet H. Kocoglu, MD, Shebli Atrash, MD, Chris Ferreri, MD, Omar Castaneda, MD, James A Davis, PharmD, Evguenia Ouchveridze, MD, Joseph P. McGuirk, DO, Charlotte B Wagner, PharmD, Radhika Bansal, MBBS, Patrick Costello, MS, Kinaya Smith, MD, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, MD, Hitomi Hosoya, MD, PhD, Lekha Mikkilineni, MD, MA, Laura B. Oswald, PhD, Gurbakhash Kaur, MD, MA, Oren Pasvolsky, MD, Mahmoud R. Gaballa, MD, Megan M Herr, PhD, Peter A. Forsberg, MD, Murali Janakiram, MBBS, Myo Htut, MD, Sireesha Asoori, MBBS, MPH, Nilesh Kalariya, PhD, RN, Hamza Sloan Hashmi, MD, Ran Reshef, MD, MSc, Douglas W Sborov, MD, Omar Nadeem, MD, Faiz Anwer, MD, Jack Khouri, MD, Shahzad Raza, MD, Djordje Atanackovic, MD, Melissa Alsina, MD, Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP, Frederick L. Locke, MD, Peter M. Voorhees, MD, Larry D Anderson Jr., MD, PhD, Shambavi Richard, MD, Thomas Martin, MD, Yi Lin, MD, PhD, Krina K. Patel, MD, MSc and Surbhi Sidana, MD 
 
1062 | Overcoming Immune Escape Via Targeting Akt-Wnt/β-Catenin By Artificial-Intelligence-Powered Peptide-Producing mRNAs
Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs
Program: Oral and Poster Abstracts
Type: Oral
Time: 5:45 PM
Location: Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
Zhe Yang, PhD, Negin Manshour, Xi He, MD,. Ph.D., Michael Epp, Jay Unruh, Ph.D., Xinjian Mao, PhD, Ruochen Dong, Ph.D., Dan Bradford, Shengping Huang, Ph.D, Fengyan Deng, Ph.D, Mark Hembree, Chongbei Zhao, Ph.D, Liang Xu, M.D., Ph.D., Dong Xu, Ph.D and Linheng Li, Ph.D.
  
5030 | The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART
Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Hannah Katz, PsyD, Lauren N Scott, Pilar Thangwaritorn, BS, Jianzheng Wu, William Wesson, MD, MPH, Dinesh Pal Mudaranthakam, PhD, Shaun DeJarnette, Al-Ola Abdallah, MD, Marc Hoffmann, MD, Forat Lutfi, MD, Sunil Abhyankar, MD, Leyla O. Shune, MD, Muhammad Umair Mushtaq, MD, Anurag Singh, MD, Haitham Abdelhakim, MD, Joseph P. McGuirk, DO, Muhammad Mahdi Nashatizadeh, MD, Liz Muenks, PhD and Nausheen Ahmed, MD

5040 | Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Ishita Kamboj, Jordan Snyder, PharmD, Chelsea Gorsline, Dilek Ince, MD, Aneela Majeed, MD, Faiz Anwer, MD, Hira Shaikh, MD, Abdullah Mohammad Khan, MD, MBBS, Al-Ola Abdallah, MD, Kimberly M Green, DO, Shebli Atrash, MD, Claire Yun Kyoung Ryu Tiger, MD, Prerna Mewawalla, Barry Paul, MD, MS and Nausheen Ahmed, MD
 
5044 | Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina
Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Marie Michele Sainvil, MD, Melissa Lowe, MS, Delaney Underwood, MS, Yan Li, PhD, Tomi F. Akinyemiju, PhD, MS., Taewoong Choi, MD, Cristina Gasparetto, MD, Mitchell Horwitz, MD, Gwynn D. Long, MD, Richard Lopez, MD, Stefanie Sarantopoulos, MD, PhD, Edwin Alyea III, MD, Nelson J. Chao, MD, Thomas W. LeBlanc, MD, MA, MS, Yubin Kang, MD, Suzanne Kirby, MD, PhD, Chenyu Lin, MD, Matthew Stuart McKinney, MD, Alexandra Stefanovic, MD, Jie Wang, MD, MS, Andrea Sitlinger, MD, Sendhilnathan Ramalingam, MD, Anthony D. Sung, MD and Sanghee Hong, MD 
 
5045 | Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma
Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center) 
Fathima Shehnaz Ayoobkhan, MD, Sara Shatnawi, MD, Moazzam Shahzad, MD, Aqeeb Ur Rehman, MD, Sohaib Irfan, MD, Raabia Qureshi, Arooq Khalid, Sibgha Gull Chaudhary, MD, Faiz Anwer, MD, Briha Ansari, Joseph P. McGuirk, DO, Mohamad Mohty, MD, PhD, Nausheen Ahmed, MD, Al-Ola Abdallah, MD and Muhammad Umair Mushtaq, MD
 
5162 | Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Michael Weise, PharmD, Shebli Atrash, MD, Briha Ansari, Muhammad Umair Mushtaq, MD, Joseph P. McGuirk, DO, Al-Ola Abdallah, MD, Zahra Mahmoudjafari, PharmD and Nausheen Ahmed, MD
 
5163 | Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Fathima Shehnaz Ayoobkhan, MD, Raabia Qureshi, Raeef L Rahman, BS, Zohaa Faiz, Sohaib Irfan, MD, Ahmad Iftikhar, MD, Briha Ansari, Muhammad Umair Mushtaq, MD, Al-Ola Abdallah, MD, Shahzad Raza, MD, Hira Shaikh, MD, Forat Lutfi, MD, Shebli Atrash, MD, Joseph P. McGuirk, DO, Hamza Sloan Hashmi, MD, Faiz Anwer, MD and Nausheen Ahmed, MD
 
5170d | Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Hira Shaikh, MD, Jonathan Lochner, PharmD, Bradley Loeffler, Reed Friend, MD, Alma Habib, MD, Marshall McKenna, MD, Jordan Snyder, PharmD, James A Davis, PharmD, Gina Patrus, Rachel Dileo, Prerna Mewawalla, Kimberly M Green, DO, Muhammad Umair Mushtaq, MD, Christopher Strouse, MD, Yun Kyoung Tiger, MD, PhD, Al-Ola Abdallah, MD, Nausheen Ahmed, MD, Abdullah Mohammad Khan, MD, MBBS, Hamza Sloan Hashmi, MD, Barry Paul, MD, MS and Shebli Atrash
 
5170e | Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents
Session: 907. Outcomes Research: Plasma Cell Disorders: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Mehndi Dandwani, MBBS, Aliya Rashid, DO, MPH, Donald C Moore, PharmD, BCPS, BCOP, DPLA, FCCP, Julia Balmaceda, MD, Belal Abousaida, MD, PhD, Aishwarya Sannareddy, MBBS, Paige Laverick, Prerna Rastogi, MD, PhD, Abdullah Thayyil, James A Davis, PharmD, Kimberly M Green, DO, Christopher Strouse, MD, Aimaz Afrough, Barry Paul, MD, MS, Hamza Sloan Hashmi, MD, Larry D Anderson Jr., MD, PhD, Nausheen Ahmed, MD, Al-Ola Abdallah, MD, Shebli Atrash and Hira Shaikh, MD
 
4921 | Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Neel S. Bhatt, MBBS, MPH, Elizabeth M Hellewell, BS3*, Kevin Ng, M.S., Ted Gooley, PhD, Anthony D. Sung, MD, Allison O. Taylor, MD, MS, Sanghee Hong, MD, Nausheen Ahmed, MD, Cherie Morey, MD, Sarah Fitzmaurice, Vanessa E. Kennedy, MD, Michelle Lauer, Andrew D. Trunk, MD, Betty K. Hamilton, MD, Akshay Sharma, MBBS, Zoey Phelps-Bergeron, LaQuisa Hill, MD, Rawan Faramand, MD, Hien Liu, MD, Lena E Winestone, MD, Geoffrey Cheng, Manuel Espinoza-Gutarra, MD, Omer Jamy, MD, Maria Odstrcil Bobillo, MD, Brian McClune, DO, Mariam T. Nawas, MD, Samuel J. Yates, MD, MSc, Miki Nishitani, MD, BS, Takuto Takahashi, MD, PhD, Jane Koo, MD, Kasiani C Myers, MD, Kris Michael Mahadeo, MD, Andrea Bauchat, DO, Laurie K Pearson, MD, Ritika Walia, MD, Kelsea Seago, PharmD, RPh, Spencer Yingling, PharmD, Cory Edgar, PA-C, Amy Browning, APRN and Catherine J. Lee, MD, MSc 
 
4932 | Outcomes with Venetoclax and Hypomethylating Agents in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Moazzam Shahzad, MD, Aqsa Mumtaz, MD, MBBS, Ahmad Basharat, Sohaib Irfan, MD, Muhammad Hamza Sadiq, MBBS, Faryal Altaf, MD, Sarah Faisal, Numan Akram, Muhammad Zeeshan, Muhammad Kashif Amin, MD, Sibgha Gull Chaudhary, MD, Iqra Anwar, MBBS, Matthew McGuirk, Anurag Singh, MD and Muhammad Umair Mushtaq, MD
 
4936 | Correlates of Patient-Reported Outcomes Following Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Moazzam Shahzad, MD, Zouina Sarfraz, MBBS, Ben Ponvilawan, MD, Muhammad Kashif Amin, MD, Matthew McGuirk, Sibgha Gull Chaudhary, MD, Robin Park, Iqra Anwar, MBBS, Raheel Iftikhar, MBBS, FCPS, Nausheen Ahmed, MD, Mehdi Hamadani, MD, Joseph P. McGuirk, DO and Muhammad Umair Mushtaq, MD
 
4860 | Impact of Conditioning Intensity on Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Patients with Acute Leukemia and Myelodysplastic Syndromes
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Moazzam Shahzad, MD, Muhammad Kashif Amin, MD, Aqeeb Ur Rehman, MD, Aleenah Mohsin, Matthew McGuirk, Sibgha Gull Chaudhary, MD, Iqra Anwar, MBBS, Haitham Abdelhakim, MD, Anurag K. Singh, MD, Mehdi Hamadani, MD, Joseph P. McGuirk, DO and Muhammad Umair Mushtaq, MD
 
4877 | Outcomes after Bone Marrow Versus Peripheral Blood Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center) 
Muhammad Umair Mushtaq, MD, Amir Kasaeian, Sibgha Gull Chaudhary, MD, Muhammad Kashif Amin, MD, Naghmeh Khavandgar, Hediyeh Alemi, Muhammad Fareed Khalid, MD, Iqra Anwar, MBBS, Matthew McGuirk, Anurag K. Singh, MD, Joseph P. McGuirk, DO and Moazzam Shahzad, MD
 
4065 | Immune Checkpoint Inhibitors Reverse the Mesenchymal Stromal Cell-Mediated Immunosuppression in Acute Myeloid Leukemia Microenvironment
Session: 506. Bone Marrow Microenvironment: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Rong Xin Liu, Meizhang Li, PhD, Harsh B. Pathak, PhD, Tara L. Lin, MD, Barry S. Skikne, MD, Joseph P. McGuirk, DO, Omar Aljitawi, MD, Andrew K. Godwin, PhD and Haitham Abdelhakim, MD
 
1306 | Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
Session: 506. Bone Marrow Microenvironment: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Ruochen Dong, Ph.D., Hua Li, Ph.D., Xi He, MD,. Ph.D., Chen Wang, Anoja Perera, Seth Malloy, Jonathon Russell, Wenting Li, Kaitlyn Petentler, Xinjian Mao, PhD, Zhe Yang, PhD, Michael Epp, Kate Hall, Allison Scott, Mary C McKinney, Shengping Huang, Ph.D, Sarah Smith, Mark Hembree, Yongfu Wang, Zulin Yu, Jeff Haug, Jay Unruh, Ph.D., Brian Slaughter, Xunlei Kang, PhD and Linheng Li, Ph.D.
 
4742 | Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Rachel Dileo, Prerna Mewawalla, MD, Gina Patrus, Christopher Strouse, MD, Ethan Chen, MD, Hira Shaikh, MD, James A Davis, PharmD, Kimberly M Green, DO, Omar Alkharabsheh, MBBS, Aliya Rashid, DO, MPH, Bidushi Pokhrel, Nausheen Ahmed, MD, Al-Ola Abdallah, MD and Hamza Sloan Hashmi, MD
 
4670 | Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis
Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Moazzam Shahzad, MD, Zobia Farooq, Amina Akram, MD, Ben Ponvilawan, MD, Rimsha Riaz, Mashood Ahmad Farooqi, Saba Ambreen Awan, Sibgha Gull Chaudhary, MD, Iqra Anwar, MBBS, Shajadi Patan, MD, Muhammad Kashif Amin, MD, Leyla O. Shune, MD, Al-Ola Abdallah, MD, Joseph P. McGuirk, DO and Muhammad Umair Mushtaq, MD
 
4823 | Inb-100: Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma Delta T Cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Joseph P. McGuirk, DO, Sunil Abhyankar, MD, Trishna Goswami, MD, MBA, Mariska ter Haak, Kate Rochlin, PhD and Lawrence S. Lamb, PhD
 
4829 | CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Armin Ghobadi, MD, Joseph P. McGuirk, DO, Paul Shaughnessy, MD, Constantine S. Tam, MBBS, MD, Melanie Allen, MS, Chenyi Pan, PhD, Ziliang Li, PhD, William N. Stevens, MS, Annie Weaver, PhD and Chan Y. Cheah, MBBS DMSc
 
4503 | CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
Session: 628. Aggressive Lymphomas: Cellular Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Alexandra E. Rojek, MD, Nausheen Ahmed, MD, Marina Gomez Llobell, MD, MS, Sairah Ahmed, MD, Marie Hu, MD, Monica Mead, MD, Andy Chen, MD, PhD, Vivek Patel, MD, Jamie Brower, MS, Veronika Bachanova, MD, PhD, Richard T. Maziarz, MD, Olalekan O. Oluwole, MD, MPH, MBBS, Michael R Bishop, MD, David L. Porter, MD, Miguel Angel Perales, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD and Daniel J. Landsburg, MD
 
3862 | Transcriptional Control of Gene Expression By O-Glcnacylation during Erythropoiesis
Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Kenneth R Peterson, PhD, Matthew P Parker, PhD, Aspin Denson, BS, Will Brautman, BS, Nick Lowe, BS, Halyna Fedosyuk, MS, Lesya V Novikova, PhD, Jeffrey A Thompson, PhD, Jennifer J Kohler, PhD and Chad Slawson, PhD
 
2873 | A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
John F. DiPersio, MD, PhD, Guenther Koehne, MD, PhD, Nirali N. Shah, MD, Lea Bernard, MD, Hyung C Suh, MD, PhD, Divya Koura, MD, Miguel Angel Perales, MD, Roni Tamari, MD, Muhammad Umair Mushtaq, MD, Joseph E. Maakaron, MD, Michael R. Loken, PhD, Darren A Stanizzi, Melissa M. Lee-Sundlov, Ph.D., Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, MD, PhD and Brenda W Cooper, MD
 
4256 | Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Prateek Pophali, MBBS, Giulia Cheloni, PhD, Richard M. Stone, MD, Kai W Wucherpfennig, MD, PhD, Aric C. Hall, MD, Amir T. Fathi, MD, Lina Bisharat, MS, Emma K Logan, Yiwen Liu, MS, Donna S. Neuberg, ScD, Malgorzata McMasters, MD, Jessica Liegel, MD, Jacqueline S. Garcia, MD, Daniel J. DeAngelo, MD, PhD, Michele Narcis, Dina Stroopinsky, PhD, Pavania Elavalakanar, MSc, BSc, Ioannis S Vlachos, PhD, Ilene A. Galinsky, MSN, ANP-C, Jason Pyrdol, Georges Chedid, MD, Dimitra Karagkouni, PhD, Shivani Nanda, Kathrine S Rallis, MBBS, MSc, Isabella Saldarriaga, BS, Hazal Toros, MS, Haitham Abdelhakim, MD, Amelia Langston, MD, Joseph P. McGuirk, DO, Donald Kufe, MD, David Avigan, MD and Jacalyn Rosenblatt, MD 
 
4204 | A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Amanda M Li, MD, Catherine Aftandilian, MD, Susan Colace, MD, MSc, Sarah Fanizzi, BA, CCRP, Kelly Elizabeth Faulk, MD, Erin M. Guest, MD, Ammar Hayani, MD, Richard Ho, MD, Anjali Khanna, MBBS, MPH, Kasey Leger, MD, MSc, David McCall, MD, Tamara P. Miller, MD, MSCE, Holly Pacenta, MD, Troy Quigg, Jeremy D. Rubinstein, MD, PhD, Deepa Bhojwani, MD, Susan R Rheingold, MD, Maureen M. O'Brien, MD and Karen R Rabin, MD, PhD
 
4211 | Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
Session: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Nikolai A. Podoltsev, MD, PhD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Elisabeth Paietta, PhD, Kathryn G. Roberts, Yanming Zhang, MD, Janis Racevskis, PhD, Hillard M. Lazarus, MD, Jacob M. Rowe, MD, Daniel A. Arber, MD, Matthew J. Wieduwilt, MD, Michaela Liedtke, MD, Julie Bergeron, MD, Brent L. Wood, MD, PhD, Yaqi Zhao, MSc, Gang Wu, PhD, Ti-Cheng Chang, PhD, Wenchao Zhang, PhD, Keith W. Pratz, MD, Shira N. Dinner, MD, Noelle Frey, MD, MS, Steven D. Gore, MD, Bhavana Bhatnagar, DO, Ehab L. Atallah, MD, Geoffrey L. Uy, MD, Deepa Jeyakumar, MD, Tara L. Lin, MD, Cheryl L. Willman, MD, Daniel J. DeAngelo, MD, PhD, Shejal B. Patel, DO, Michelle A Elliott, MD, Anjali S. Advani, MD, Dimitrios Tzachanis, Pankit Vachhani, MD, Rupali Roy, MD, Elad Sharon, MD, MPH, Richard F. Little, MD, MPH, Harry Erba, MD, PhD, Richard M. Stone, MD, Charles G. Mullighan, MBBS, MSc, MD, Martin S. Tallman, MD, Selina Luger, MD, FRCPC and Ryan J Mattison, MD 
 
4042 | Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow
Session: 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Xinjian Mao, PhD, Ning Zhang, Ph.D., Xi He, MD,. Ph.D., Ruochen Dong, Ph.D., Zhe Yang, PhD, Michael Epp, Linda Zhang, Allison Scott, Kate Hall, Anoja Perera, Jeff Haug, Hua Li, Ph.D., Cheng Luo, Ph.D., Chuan He, Ph.D. and Linheng Li, Ph.D.
 
4256 | Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Prateek Pophali, MBBS, Giulia Cheloni, PhD, Richard M. Stone, MD, Kai W Wucherpfennig, MD, PhD, Aric C. Hall, MD, Amir T. Fathi, MD, Lina Bisharat, MS, Emma K Logan, Yiwen Liu, MS, Donna S. Neuberg, ScD, Malgorzata McMasters, MD, Jessica Liegel, MD, Jacqueline S. Garcia, MD, Daniel J. DeAngelo, MD, PhD, Michele Narcis, Dina Stroopinsky, PhD, Pavania Elavalakanar, MSc, BSc, Ioannis S Vlachos, PhD, Ilene A. Galinsky, MSN, ANP-C, Jason Pyrdol, Georges Chedid, MD, Dimitra Karagkouni, PhD, Shivani Nanda, Kathrine S Rallis, MBBS, MSc, Isabella Saldarriaga, BS, Hazal Toros, MS, Haitham Abdelhakim, MD, Amelia Langston, MD, Joseph P. McGuirk, DO, Donald Kufe, MD, David Avigan, MD and Jacalyn Rosenblatt, MD 
 
3947 | Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Moazzam Shahzad, MD, Shahzaib Ahmed, Eeman Ahmad, Umar Akram, Haider Ashfaq, Hamza Ashraf, Sudeepthi Bandikatla, MBBS, Qamar Iqbal, MD, Turab Mohammad, Atif Butt, MD, Muhammad Umair Mushtaq, MD and Michael V. Jaglal, MD
 
4623 | Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Alan P Skarbnik, MD, Alexey V. Danilov, MD, PhD, Marc Hoffmann, MD, Farrukh T. Awan, MD, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, PhD, Alan SM Yong, MD, Vikram Shetty, MD, John N. Allan, MD and Jennifer A. Woyach, MD
 
4324 | Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Uma Borate, MD, Ying Huang, MS, MA, Rina Li Welkie, MPH, Ronan T. Swords, MD, PhD, FRCP, FRCPath, Elie Traer, MD, PhD, Eytan M. Stein, MD, Tara L. Lin, MD, Yazan F Madanat, MD, Prapti A. Patel, MD, Robert H. Collins, MD, Maria R. Baer, MD, Vu H. Duong, MD, MS, William Blum, MD, Martha L. Arellano, MD, Wendy Stock, MD, Olatoyosi Odenike, MD, Robert L. Redner, MD, Tibor J. Kovacsovics, MD, Michael W. Deininger, MD, PhD, Joshua F. Zeidner, MD, Rebecca Olin, MD, Catherine C. Smith, MD, James M. Foran, MD, Gary J. Schiller, MD, Emily K Curran, MD, Kristin L Koenig, MD, Nyla A. Heerema, PhD, Timothy Chen, PhD, Molly Martycz, Mona Stefanos, MD, Sonja Gullen Marcus, MPH, Leonard Rosenberg, Brian J. Druker, MD, Ross L Levine, MD, Amy Burd, PhD, Ashley Owen Yocum, PhD, Alice Mims, MD30 and John C. Byrd, MD 
 
4325 IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
Session: 618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Fieke W Hoff, MD, PhD, Ying Huang, MS, MA, Rina Li Welkie, MPH, Ronan T. Swords, MD, PhD, FRCP, FRCPath, Elie Traer, MD, PhD, Eytan M. Stein, MD, Tara L. Lin, MD, Prapti A. Patel, MD, Robert H. Collins, MD, Maria R. Baer, MD, Vu H. Duong, MD, MS, William Blum, MD, Martha L. Arellano, MD, Wendy Stock, MD, Olatoyosi Odenike, MD, Robert L. Redner, MD, Tibor J. Kovacsovics, MD, Michael W. Deininger, MD, PhD, Joshua F. Zeidner, MD, Rebecca Olin, MD, Catherine C. Smith, MD, James M. Foran, MD, Gary J. Schiller, MD, Emily K Curran, MD, Kristin L Koenig, MD, Nyla A. Heerema, PhD, Timothy Chen, PhD, Molly Martycz, Mona Stefanos, MD, Sonja Gullen Marcus, MPH, Leonard Rosenberg, Brian J. Druker, MD, Ross L Levine, MD, Amy Burd, PhD, Ashley Owen Yocum, PhD, Uma Borate, MD, Alice Mims, MD, John C. Byrd, MD and Yazan F. Madanat, MD 
 
4911 | Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Robert J. Soiffer, MD, Mitchell Horwitz, MD, Joseph P. McGuirk, DO, Sudhindra Rao, PhD, Peter Westervelt, MD, John F. DiPersio, MD, PhD, Laura Johnston, MD, Jonathan Serody, MD, Witold B Rybka, MD, Paul Shaughnessy, MD, Joseph A. Pidala, MD, PhD, Vincent Ho, MD, Andrew Artz, MD, MS, Madhuri Vusirikala, MD, David L. Porter, MD, Paul J. Martin, MD, David Avigan, MD, Michael R Bishop, MD, Ran Reshef, MD, MSc, Andrew Peterson, Kwang Wooahn, PhD, Adetola A. Kassim, MD, MBBS, MS, Ryotaro Nakamura, MD, Yi-Bin Chen, MD, MS and Linda Burns 
 
4559 | Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Program: Oral and Poster Abstracts
Type: Poster
Time: 6 - 8 PM
Location: Halls G-H (San Diego Convention Center)
Aaron T. Gerds, MD, MS, Andrew T. Kuykendall, MD, Marina Kremyanskaya, MD, PhD, Ellen K. Ritchie, MD, Jason Gotlib, MD, MS, Jeanne Palmer, MD, Kristen M. Pettit, MD, Victor Priego, MD, Uttam Kumar Nath, MD, DM, Abdulraheem Yacoub, MD, Arkapal Bandyopadhyay, MD, DNB, DM, Suneel Gupta, PhD, Sarita Khanna, PhD, Arturo Molina, MD, MS, FACP and Naveen Pemmaraju, MD

December 10, 2024

Impact and Types of Exercise and Pharmacotherapy in Weight Loss
Session Title: Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction
Time: 12 - 1:30 PM
Session Location: Hemisfair Ballroom 1-2 
Moderator: Carol J. Fabian
Presenter: John Jakicic

*The below content was pulled from currently available information on ASTRO's website as well as supplied by KU Cancer Center members.

September 29, 2024

PS 03 - Presidential Symposium: Innovations in Genitourinary Cancers: Session III - Radiotherapy for Prostate Cancer: Innovations You Can Implement Today

Session Date/Time: September 29, 11:10 AM - 12 PM

Session Location: Ballroom A/B/C

Moderator: Ronald Chen, MD, FASTRO, MPH

SS 04 - PRO/QoL/Survivorship 1: New Frontiers in Patient Reporting Outcomes and Survivorship

Session Date/Time: September 29, 2:45 - 4 PM

Session Location: Room 204

Moderator: Tamara Vern-Goss, DO, FAAP and Xinglei Shen, MD

October 1, 2024

EDU 56 - Perspectives from a Physicist, Biologist and Clinician: Unrealized Opportunities in Spatially Fractionated Radiotherapy

Session Date/Time: October 1, 5:15 - 6:15 PM

Session Location: Room 145

Moderator: Gregory Gan, MD, PhD

October 2, 2024

Abstracts/Posters

May 31, 2024

Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.
2:45 pm – 4:15 pm
E451 | On Demand
Rapid Oral Abstract Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract: 515
Yara Abdou, Jess Hoag, William Barlow, Julie Gralow, Funda Meric-Bernstam, Kathy Albain, Daniel Hayes, Nancy Lin, Edith Perez, Lori Goldstein, Stephen Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Anne Schott, Jennifer Racz, Debashish Tripathy, Gabriel Hortobagyi, Lajos Pusztai, Priyanka Sharma, Kevin Kalinsky

Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.
8 am – 9:30 am
E450b | On Demand
Rapid Oral Abstract Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies
Abstract: 6511
Maro Ohanian, Maher Abdul-Hay, Tara Lin, Ellen Ritchie, Vamsi Kota, Miranda Lim, Sherry Pierce, Michael Hickey, Ana Tari Ashizawa, Hagop Kantarjian, Jorge Cortes, Gail Roboz

A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract: 3112, Poster Bd #: 257
Frank Tsai, Michael Birrer, Jason Brown, Sanjay Chandrasekaran, Vincent Chung, Richard Frank, Edward Garmey, Shirish Gadgeel, Thomas George, Shadia Jalal, Andrew Poklepovic, Jennifer Segar, Alexander Spira, Jue Jillian Zhang, Anup Kasi

A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.
9 am – 12 pm 
Hall A | On Demand
Poster Session
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract: 3077, Poster Bd #: 222
Thatcher Heumann, Shannon Stockton, Michael Cecchini, Raid Aljumaily, Cathy Shyr, Jennifer Whisenant, Jason Starr, Farshid Dayyani, Joaquina Baranda, Nikolaos Trikalinos, S. Ivy, Patricia LoRusso, Satya Das, Steven Gore, Jan Beumer, Jordan Berlin

An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT 112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract: TPS2677, Poster Bd #: 152a
Salman Punekar, Meredith Pelster, Carlos Becerra, J. Hecht, Andrew Paulson, Patrick Grierson, Maria Pia Morelli, Rom Leidner, Mandana Kamgar, Joaquina Baranda, Syed Kazmi, Ardaman Shergill, Anne Robinson, Anuradha Patel, Ying Yan, Jeroen van Heijst, Nathan Demars, Arianne Perez, Sarah Cohen, Marwan Fakih

Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract: TPS2685, Poster Bd #: 156a
Percy Lee, Jyoti Malhotra, Jason Salsamendi, Mona Arbab, Tithi Biswas, Andrew Baschnagel, Matthew Deek, Edward Garmey, Daniel Hamstra, Mai Anh Huynh, Aryavarta Kumar, Devalingam Mahalingam, Benjamin Maughan, Teresa Mooneyham, Nitin Ohri, Krishna Reddy, Gregory Vlacich, Patrick Widhelm, Jason Ye, Robert Timmerman

ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Developmental Therapeutics—Immunotherapy
Track: Developmental Therapeutics—Immunotherapy
Abstract: TPS2675, Poster Bd #: 151a
Ashley Hamilton, Robin Kate Kelley, Daneng Li, Ignacio Melero Bermejo, Ghassan Abou-Alfa, Olatunji Alese, Raed Al-Rajabi, Hani Babiker, Mitesh Borad, Farshid Dayyani, Martin Gutierrez, Jung Yong Hong, Lionel Aurelien Kankeu Fonkoua, Thomas Karasic, Adel Kardosh, Bridget Keenan, Anne Noonan, Anwaar Saeed, Attilio Bondanza, John Stone

Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4109, Poster Bd #: 89
Masatoshi Kudo, Ann-Lii Cheng, Philippe Merle, Baek-Yeol Ryoo, Thomas Decaens, Irfan Cicin, Olav Dajani, Raed Al-Rajabi, Jean-Marie Peron, Stephen Chan, Jennifer Knox, Bruno Daniele, Leah Suttner, Andrea Webber, Carol Pena, Razvan Cristescu, Cai Chen, Ken Hatogai, Abby Siegel, Richard Finn

Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Colorectal and Anal
Track: Gastrointestinal Cancer—Colorectal and Anal
Abstract: 3598, Poster Bd #: 261
Anup Kasi, Raed Al-Rajabi, Weijing Sun, Joaquina Baranda, Haoran Li, Jo Wick, Sanjana Mullangi, Kenda Eberhardt, Shannon Bradbury, Rebecca Romero, Erin Carroll, Lori Barbosa, Mazin Al-Kasspooles, Anwaar Saeed

Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Melanoma/Skin Cancers
Track: Melanoma/Skin Cancers
Abstract: TPS9608, Poster Bd #: 387b
Muhammad Umair Mushtaq, Haitham Abdelhakim, Luke Selby, Sunil Abhyankar, Joseph McGuirk, Gary Doolittle

Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4175, Poster Bd #: 155
Deirdre Cohen, Judith Goldberg, Lawrence Leichman, Tsivia Hochman, Elliot Newman, Kevin Du, Alec Megibow, Paul Oberstein, Raed Al-Rajabi, Aaron Scott, Tanios Bekaii-Saab, Wells Messersmith, Colin Weekes

ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4168, Poster Bd #: 148
S. Lindsey Davis, Anup Kasi, Farshid Dayyani, Allyson Ocean, Vincent Chung, Mohammed Najeeb Al Hallak, Christos Fountzilas, Junxiao Hu, Judy Murray, Carmen Allegra, Steven Gore, Jan Beumer, Karyn Goodman

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4046, Poster Bd #: 26
Kei Muro, Keisho Chin, Steven Maron, Fadi Braiteh, Seiichiro Mitani, Hiroki Hara, Yasutoshi Kuboki, Mary Mulcahy, Joaquina Baranda, Faithlore Gardner, Ning Jin, Satoshi Hamauchi, Jason Kaplan, Seema Gorla, Shubin Liu, Michele Wozniak, Changting Meng, Shunsuke Kondo

Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Sarcoma
Track: Sarcoma
Abstract: 11526, Poster Bd #: 452
Kristine Lacuna, Matthew Ingham, Li Chen, Biswajit Das, Shing Lee, Liner Ge, Mihaela Druta, Anthony Conley, Mary Louise Keohan, Mark Agulnik, Melissa Burgess, Anna Chalmers, Gina D'Amato, Benjamin Powers, Mahesh Seetharam, Brittany Siontis, Lorraine Pelosof, Brian Van Tine, Gary Schwartz, Mia Weiss

Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
3 pm – 6 pm
Arie Crown Theater | Live Stream
Oral Abstract Session
Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile
Track: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract: 5006
Ronald Chen, Gina Mazza, Briant Fruth, Han Xiao, Joel Picus, Mary Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Daniel Shevrin, James Mohler, Daniel Anderson, Arpit Rao, Alan Tan, Charles Ryan, Scott Eggener, Michael Morris, Rahul Aggarwal

Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.
3 pm – 6 pm
Hall B1 | Live Stream
Oral Abstract Session
Session Title: Breast Cancer—Metastatic
Track: Breast Cancer
Abstract: 1005
Antonio Giordano, Arif Ali Awan, Justine Yang Bruce, Hope Rugo, Jennifer Diamond, Yelena Novik, Joaquina Baranda, Kei Muro, Makiko Ono, Rita Nanda, Jason Kaplan, Seema Gorla, Shubin Liu, Michele Wozniak, Anthony Lee, Tiffany Traina

Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.
3 pm – 6 pm
S100bc | Live Stream
Oral Abstract Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract: 7007
Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Rubén Fernández-Álvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Maoko Naganuma, Edith Szafer-Glusman, Jennifer Lin, James Dean, Jutta Neuenburg, Constantine Tam

June 2, 2024

NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).

9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Breast Cancer – Local/Regional/Adjuvant
Track: Breast Cancer
Abstract: TPS629, Poster Bd #: 212a
Shane Stecklein, Allison Aripoli, Roberto Salgado, Anne O'Dea, Lauren Nye, Kelsey Larson, Deepti Satelli, Ryan Rader, Rashna Madan, Rachel Yoder, Joshua Staley, India Fernandez, Adam Heinrich, Jamie Wagner, Christa Balanoff, Lyndsey Kilgore, Leonidas Bantis, Andrew Godwin, Qamar Khan, Priyanka Sharma

June 3, 2024

Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).
8 am – 11 am
Hall B1 | Live Stream
Oral Abstract Session
Session Title: Genitourinary Cancer—Kidney and Bladder
Track: Genitourinary Cancer—Kidney and Bladder
Abstract: 4501
Jill Hamilton-Reeves, Joseph Unger, Jeffrey Holzbeierlein, Danika Lew, James Ryan Mark, Siamak Daneshmand, Janet Kukreja, Eugene Lee, William Tabayoyong, Dawn Hershman, Michael Fisch, Norah Henry

Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract: 7041, Poster Bd #: 24
Morgan Zenner, Spencer Lessans, Kai Rejeski, Miguel-Angel Perales, Richard Maziarz, Andy Chen, David Porter, Stephen Schuster, Joseph McGuirk, Michael Bishop, Veronika Bachanova, Loretta Nastoupil, Peter Riedell, Olalekan Oluwole, Shakthi Bhaskar, Vivek Patel

Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies
Abstract: TPS7085, Poster Bd #: 67a
Armin Ghobadi, Caron Jacobson, Joseph McGuirk, Nirali Shah, John Rossi, Tonia Buchholz, Lizamarie Bachier-Rodriguez, John Baird, Catherine Diefenbach, Umar Farooq, Francisco Hernandez-Ilizaliturri, Iris Isufi, Krish Patel, Sattva Neelapu, Craig Sauter, Jay Spiegel, Michael Tees, John Timmerman, Ginna Laport, Matthew Frank

VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies
Abstract: TPS6592, Poster Bd #: 147b
Aniket Bankar, Kristen Pettit, Joseph Shatzel, Abdulraheem Yacoub, Naveen Pemmaraju, Harinder Gill, Antonin Hlusi, Alessandro Lucchesi, Samah Alimam, Jiří Mayer, Francesca Palandri, Daniel Sasca, Katharina Modelska, Suneel Gupta, Ifode Ajari, Sarita Khanna, Arturo Molina, Andrew Kuykendall

A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
9 am – 12 pm
Hall A | On Demand
Poster Session
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track: Hematologic Malignancies
Abstract: TPS6590, Poster Bd #: 146b
Daniel Weiss, Courtney Dinardo, Stephen Strickland, Barry Skikne, Amer Zeidan, Elie Traer, Hetty Carraway, Stanley Frankel, Jacky Wang, Steven Pirie-Shepherd, Joseph Piccotti, Duncan Hamish Wright, Karen Akinsanya

Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Lung Cancer—Non-Small Cell Metastatic
Track: Lung Cancer
Abstract: 8585, Poster Bd #: 449
Kei Muro, Trevor Feinstein, Joaquina Baranda, Ioana Bonta, Satoru Kitazono, Todd Gersten, Leena Gandhi, Toshihiro Kudo, Jason Kaplan, Seema Gorla, Shubin Liu, Michele Wozniak, Anthony Lee, Tejas Patil

Young adults (YA) with non-small cell lung cancer (NSCLC): Snapshot of the oncogenic drivers and immune landscapes.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Lung Cancer—Non-Small Cell Metastatic
Track: Lung Cancer
Abstract: 8538, Poster Bd #: 402
Aaron Pruitt, Robert Hsu, Nishant Gandhi, Coral Olazapasti, Estelamari Rodriguez, Dwight Owen, Jinesh Gheeya, Jun Zhang, Muhammad Furqan, Jaclyn LoPiccolo, Andrew Elliott, Ari VanderWalde, Stephanie Rock, Patrick Ma, Balazs Halmos, Zhonglin Hao

Predictive models as a clinical decision support tool for genetic cancer risk assessment among Mexican patients at risk of hereditary colorectal cancer.
1:30 pm – 4:30 pm
Hall A | On Demand
Poster Session
Session Title: Prevention, Risk Reduction, and Genetics
Track: Prevention, Risk Reduction, and Genetics
Abstract: 10617, Poster Bd #: 144
Jose Luis Rodriguez Olivares, Dione Aguilar y Méndez, Pamela Rivero Garcia, Alejandro Aranda-Gutierrez, Rocío Ortiz-Lopez, Sandra Santuario Facio, Augusto Rojas-Martinez, Leticia Barraza, Jazmin Arteaga Vazquez, Hector De La Mora, Tamara N. Kimball, Joanne Jeter, Jeffrey Weitzel, Yanin Chavarri Guerra

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
3 pm – 6 pm
Hall B1 | Live Stream
Oral Abstract Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract: 505
Kevin Kalinsky, William Barlow, Harsh Pathak, Julie Gralow, Kathy Albain, Daniel Hayes, Nancy Lin, Edith Perez, Lori Goldstein, Stephen Chia, Priya Rastogi, Anne Schott, Steven Shak, Debashish Tripathy, Gabriel Hortobagyi, Funda Meric-Bernstam, Priyanka Sharma, Lajos Pusztai, Alastair Thompson, Andrew Godwin

Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
3 pm – 6 pm
Hall B1 | Live Stream
Oral Abstract Session
Session Title: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract: 508
Lajos Pusztai, Jess Hoag, Kathy Albain, William Barlow, Salomon Stemmer, Allison Meisner, Gabriel Hortobagyi, Steven Shak, Daniel Hayes, James Rae, Frederick Baehner, Priyanka Sharma, Kevin Kalinsky

June 4, 2024

HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.
9:45 am – 12:45 pm
S100a | Live Stream
Oral Abstract Session
Session Title: Head and Neck Cancer
Track: Head and Neck Cancer
Abstract: 6005
Alan Ho, Lisle Nabell, Prakash Neupane, Marshall Posner, Emrullah Yilmaz, Jiaxin Niu, Abdul Rafeh Naqash, Alexander Pearson, Stuart Wong, Jorge Nieva, Douglas Laux, Deborah Wong, Zujun Li, Ari Rosenberg, Winston Wong, Xiaoping Qing, Corinne Iacobucci, Henning Lauterbach, Ilian Tchakov, David Pfister

Publication Only

Neurocognitive testing to predict ICANS post-CAR T. 
Publication Only
Session Title: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track: Hematologic Malignancies 
Abstract: e19003
William Wesson, Lauren Scott, Nahid Suleman, Shaun DeJarnette, Al-Ola Abdallah, Forat Lutfi, Sunil Abhyankar, Leyla Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph McGuirk, Muhammad Nashatizadeh, Elizabeth Muenks, Hannah Katz, Nausheen Ahmed

Ductal carcinoma in situ: Molecular and cellular basis of malignancy.
Publication Only
Session Title: Publication Only: Breast Cancer—Local/Regional/Adjuvant
Track: Breast Cancer
Abstract: e12582
Fariba Behbod, Emre Arslan, Qian Zhu, Yan Hong, Benjamin Strope, Jamie Wagner, Kelsey Larson, Timothy Fields, Allison Aripoli, Ashley Huppe, Onalisa Winblad, Christa Balanoff, Jessica Peterson, Molly Hill, Camron Smith, Eric Chang, Andrew Godwin, Seema Khan, Carol Fabian, Kunal Rai

Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review.
Publication Only
Session Title: Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract: e15080
William Wesson, Fathima Shehnaz Ayoobkhan, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Weijing Sun, Faiz Anwer, Gary Doolittle, Joseph McGuirk, Raed Al-Rajabi, Joaquina Baranda, Nausheen Ahmed

KANSURVIVE: Testing a telementoring model for improving cancer survivorship care in rural practice.
Publication Only
Session Title: Publication Only: Care Delivery/Models of Care
Track: Care Delivery and Quality Care
Abstract: e13791
Jennifer Klemp, Catie Knight, Edward Ellerbeck, Christie Befort, Eve-Lynn Nelson, Anne O'Dea, Prabhakar Chalise, Dorothy Hughes, Allen Greiner

Oncologic outpatient specialty palliative care referral utilization: A single institution quality improvement project.
Publication Only
Session Title: Publication Only: Quality Care/Health Services Research
Track: Care Delivery and Quality Care
Abstract: e23205
Rubina Ratnaparkhi, Elaine Pope, Ian Cook, Melissa Javellana, Andrea Jewell, Christian Sinclair, Lori Spoozak

Trends in survival in solid malignancies with synchronous brain metastases: A population-based study.
Publication Only
Session Title: Publication Only: Quality Care/Health Services Research
Track: Care Delivery and Quality Care
Abstract: e23299
Parth Sharma, Tayla Miller, Himil Mahadevia, Ifrah Fatima, Priyanka Sharma, An-Lin Cheng, Anuj Shrestha

Preliminary results of atezolizumab and pirfenidone in non-small cell lung cancer.
Publication Only
Session Title: Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract: e15197
Chao Huang, Jo Wick, Takefumi Komiya

Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States.
Publication Only
Session Title: Publication Only: Quality Care/Health Services Research
Track: Care Delivery and Quality Care
Abstract: e23287
Ronald Chen, Lisa Mucha, David Nimke, Christopher Young, Hongbo Yang, Qing Liu, Alexandra Greatsinger, Adina Zhang, Phoebe Wright, Christina Quicquaro

Racial disparities in the intervention trials in colon cancer.
Publication Only
Session Title: Publication Only: Care Delivery/Models of Care
Track: Care Delivery and Quality Care
Abstract: e13718
Abhinav Vyas, Dania Kaur, Saloni Savani, Moazzam Shahzad, Rohit Singh, Udit Yadav, Muhammad Umair Mushtaq, Akshee Batra

Underline: KUCC Members
Underline & Bold: KUCC Members that Presented

April 7, 2023

SESSION PO.CL01.05 - Spatial Proteomics and Transcriptomics
1:30 PM - 5:00 PM     
1136 / 3 - Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)
V. Mathew Thomas, B. Chigarira, G. Gebrael, C. Chehade, A. Narang, N. Sayegh, N. Tripathi, Y. Jo, C. Tandar, A. Srivastava, R. Ji, E. Dal, G. Fortuna, H. Li, B. L. Maughan, U. Swami, N. Agarwal

SESSION PO.PR01.03 - Epidemiology 
1:30 PM - 5:00 PM     
769 / 5 - Incorporating a cross-ancestry polygenic risk score into a clinical model improved breast cancer risk prediction in women with pathogenic variants
P. Tshiaba, M. Sun, D. Ratman, J. N. Weitzel, P. Shah, M. Rabinowitz, A. Kumar, K. Im

SESSION PO.PS01.10 - Environmental and Occupational Risk Factors, Infection, and Aging
1:30 PM - 5:00 PM     
844 / 17 - DNA methylation-derived immune cell profiles and risk of cancers in Black participants in the ARIC Study
C. S. Semancik, N. Zhao, D. Koestler, E. Boerwinkle, J. Bressler, K. Kelsey, E. A. Platz, D. S. Michaud

SESSION PO.TB04.04 - Membrane, Biophysical, and EMT Aspects of Motility/Metastasis
1:30 PM - 5:00 PM     
197 / 6 - The GPR52-MCAM axis as a novel regulatory mechanism of breast cancer cell clustering and metastatic potential 
S. Z. Hanif, C. C. Au, I. Torregroza, B. Bhinder, L. Dow, O. Elemento, T. Evans, K. A. Brown

SESSION PO.CL01.05 - Spatial Proteomics and Transcriptomics
1:30 PM - 5:00 PM     
1163 / 30 - Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment
A. C. Soupir, M. T. Hayes, T. C. Peak, O. E. Ospina1, N. H. Chakiryan, A. E. Berglund1, P. A. Stewart, J. Nguyen, C. M. Moran-Segura, N. L. Francis, P. M. Ramos-Echevarria, J. Chahoud, R. Li, K. Y. Tsai, J. A. Balasi, Y. Caraballo-Perez, J. Dhillon, L. A. Martinez, W. E. Gloria, N. Schurman, S. Kim, M. Gregory, J. J. Mule, B. L. Fridley, B. J. Manley

SESSION PO.TB06.01 - Developmental Origins and Drivers of Pediatric Cancer
1:30 PM - 5:00 PM      
141 / 13 - A human induced pluripotent stem cell model of KMT2A rearranged leukemia
E. Guest, M. Vacek, J. Nemechek, I. Pushel, B. T. Thornton, M. Leyda, M. S. Farooqi, J. M. Perry, J. L. Vivian

SESSION PO.BCS01.01 - Application of Bioinformatics to Cancer Biology 1
1:30 PM – 5:00 PM
876 / 20 - spatialGE: Empowering researchers to study the tumor microenvironment leveraging spatial transcriptomics
O. Ospina, R. Manjarres-Betancur, G. Gonzalez-Calderon, A. C. Soupir, I. Smalley, K. Tsai, J. Markowitz, A. Berglund, X. Yu, B. L. Fridley

SESSION MS.TB04.01 - Metastasis
3:00 PM - 5:00 PM     
Room 29 - Upper Level - Convention Center
Track(s): Tumor Biology, Tumor Microenvironment
Introduction; Chairperson, Danny R. Welch, University of Kansas Cancer Center, Kansas City, KS

April 8, 2024

SESSION PO.BCS01.12 - New Algorithms, Software, and Models
9:00 AM - 12:30 PM     
2338 / 16 - Benchmarking long- and short-read somatic structural variation callers using a multi-technology panel of six tumor/normal cell lines
A. Keskus, A. Bryant1, T. Ahmad, A. Donmez, I. Rodriguez, N. Rossi, Y. Xie, B. Yoo, R. Milano, H. Lou, J. Park, J. Gardner, B. McNulty, K. Miga, M. Dean, M. Farooqi, B. Paten, M. Kolmogorov

SESSION PO.IM01.02 - Immune Checkpoints and Inhibitory Molecules 1
9:00 AM - 12:30 PM     
1352 / 3 - Computational design of a cyclic peptide that inhibits the CTLA4 in T cells and the growth of lung carcinoma in mice
R. Thakkar, D. Upreti, S. Ishiguro, G. Magnin, K. Sudasinghe, A. Hall, S. DeVader, M. Tamura, J. Comer

SESSION PO.IM02.03 - Inflammation and Cancer in Metastasis
9:00 AM - 12:30 PM     
1399 / 19 - The role of CCN5 in regulation of tumor-infiltrating lymphocytes (TILS) in triple-negative breast cancer (TNBC) cells 
U. Biswas, A. Kambhampati, N. Haideri, A. De, S. Upadhyay, S. Banerjee, S. Banerjee

SESSION PO.MCB03.01 - Cell Signaling Components as Therapeutic Targets
9:00 AM - 12:30 PM     
1667 / 14 - The role of CCN1 in mutant K-RAS addiction in pancreatic cancer
A. Kambhampati, A. De, I. Haque, S. Banerjee, S. K. Banerjee

SESSION PO.ET09.06 - Novel Targets and Pathways
9:00 AM - 12:30 PM     
Section 29
2086 / 10 - Effect of XPO1 inhibition on colorectal cancer tumorigenesis
A. E. Evans, D. A. Dixon

SESSION PO.MCB08.02 - Genomic Characterization of Cancers and Cancer Subgroups
9:00 AM - 12:30 PM     
1763 / 18 - Long-read sequencing of pediatric leukemia identifies clinically relevant genomic rearrangements
B. Yoo, A. Keskus, C. Bi, L. Lansdon, T. Ahmad, I. Pushel, A. Walter, M. Gibson, E. Guest, T. Pastinen, M. Kolmogorov, M. S. Farooqi

SESSION PO.MCB09.02 - Metabolic Pathways 2
9:00 AM - 12:30 PM     
1783 / 5 - Understanding lipogenesis in bladder cancer
J. Leak, D. Matye, E. Abbott, B. Woolbright, J. A. Taylor III

1785 / 7 - The role of BRCA1 on metabolic pathways in an in vivo system
S. L. Hembruff, A. Dekonenko, J. Thyfault, M. Sardiu, M. Washburn, R. A. Jensen, L. M. Harlan-Williams

SESSION PO.PR02.01 - Role of Diet, Nutrition, and the Microbiome Across the Cancer Continuum
9:00 AM - 12:30 PM     
2187 / 21 - Influences of high-fat diet on tumor biology in a mouse model of colorectal cancer
A. Mahanty, C. Wallingford, R. Hammontree, M. Njoka, Z. Clark, M. Rekowski, M. Washburn, J. S. Davis

SESSION PO.BCS01.03 - Application of Bioinformatics to Cancer Biology 3
1:30 PM - 5:00 PM     
3497 / 19 - Glioma Immune Microenvironment Composition Calculator (GIMiCC): A method of estimating the proportions of eighteen key cell types from human brain tissue assayed using Illumina DNA methylation microarray technology
S. C. Pike, J. K. Wiencke, Z. Zhang, A. M. Molinaro, D. C. Koestler, B. C. Christensen, K. T. Kelsey, L. A. Salas

SESSION PO.BCS01.09 - Database Resources, Statistical Methods, and Other Tools
1:30 PM - 5:00 PM     
3562 / 22 - Comparison of spatial co-localization measures for studying the tumor immune microenvironment with application to ovarian cancer
B. L. Fridley, A. Soupir, J. Wrobel, C. Colin-Leitzinger, M. K. Townsend, A. B. Lawson, K. L. Terry, J. M. Schildkraut, S. S. Tworoger, L. C. Peres

SESSION PO.CL01.03 - Circulating Tumor Cells 1
1:30 PM - 5:00 PM     
3707 / 19 - Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
M. S. Serafini, C. Reduzzi, L. Gerratana, R. Jeselsohn, R. L. Mahtani, C. X. Ma, A. DeMichele, J. L. Meisel, K. D. Miller, Y. Abdou, E. C. Riley, R. Qamar, P. Sharma, S. Reid, H. J. Burstein, S. M. Tolaney, M. K. DeMeo, Y. Liu, E. Gauthier, Y. Ren, M. M. Regan, H. Liu, E. L. Mayer, M. Cristofanilli

SESSION PO.ET02.03 - Cancer Immunotherapy and Drug Delivery
1:30 PM - 5:00 PM    
3185 / 2 - Glatiramer acetate enhances tumor retention and mitigates systemic toxicity of toll-like receptor 9 agonists as intratumoral immunotherapy
H. Gong, D. J. Griffin, C. E. Groer, X. Wu, M. M. Abdelaziz, S. Wu, L. Xu, L. M. Forrest, C. J. Berkland

SESSION PO.MCB10.02 - microRNA- and Other Non-coding RNA-Based Translational Medicine
1:30 PM - 5:00 PM     
2998 / 15 - Regulation of epidermal growth factor receptor signaling by BRCA1-microRNA 146a network
E. Kumaraswamy, R. M. Koren Shimak, S. Gunewardena, K. L. Wendt, D. Alexander, S. L. Hembruff, R. A. Jensen

SESSION PO.PS01.07 - Biomarkers of Endogenous or Exogenous Exposures, Early Detection, Biologic Effects, and Prognosis
1:30 PM - 5:00 PM     
3424 / 8 - Assessing a DNA methylation-based telomere length estimator in individuals with a heavy smoking history
L. Grieshober, S. Graw, M. J. Barnett, G. E. Goodman, C. Chen, D. C. Koestler, C. J. Marsit, J. A. Doherty

SESSION MS.MCB08.01 - Advances in Cancer Genomics: Carcinogenesis, Tumor Evolution, and Hetero
2:35 PM – 2:50 PM
3928 - Genomic landscape and estimation of immune infiltration of soft tissue sarcoma histology subtypes from the ORIEN network
A. C. Soupir, O. E. Ospina, D. Hedges, J. K. Teer, M. D. Radmacher, D. M. McKean, N. Seligson, M. McCarter, B. Wilkey, G. Riedlinger, J. Groundland, B. J. Miller, B. Schneider, R. Patel, A. Rafeh-Naqash, S. Edge, B. Salhia, C. Moskaluk, M. Johns, M. L. Churchman, O. Hampton, D. Liebner, B. L. Fridley, A. S. Brohl

April 9, 2024

9:00 AM - 12:30 PM     
LB303 / 19 - Suppression of stress granule formation is a novel vulnerability imposed by mutant p53
E. Thoenen, A. Ranjan, A. Parrales, S. Nishikawa, D. Dixon, S. Oka, T. Iwakuma

SESSION PO.CL01.02 - Prognostic Biomarkers 1
9:00 AM - 12:30 PM     
5215 / 23 - Orphan noncoding RNA (oncRNA) liquid biopsy assay is prognostic for survival in patients with triple-negative breast cancer (TNBC) and residual disease
R. Yoder, J. Yen, M. Karimzadeh, J. M. Staley, I. Fernandez, A. C. Heinrich, F. Hormozdiari, J. Gregg, A. K. Godwin, I. Acerbi, R. Trivedi, B. Alipanahi, S. R. Stecklein, P. Sharma

SESSION PO.CL13.01 - Molecular Biology in Clinical Oncology: Genetics and Beyond
9:00 AM - 12:30 PM     
5060 / 14 - Role of molecular driver mutations in recurrence of early stage laryngeal cancer following narrow field definitive radiotherapy
A. Segura, E. Nissen, C. Lominska, R. Morse, D. Morgan, P. Neupane, D. Pei, D. Koestler, R. Kimple, U. Duvvuri, K. Sykes, S. Thomas, R. Nallani, L. Shnayder, K. Kakarala, E. Yilmaz, A. Bur

SESSION PO.IM02.01 - Adaptive Immunity in Tumors
2024, 9:00 AM - 12:30 PM     
3971 / 13 - Progesterone impacts regulatory T cell activity to promote immunosuppression in the mammary gland
E. I. Chowanec, L. R. Werner, C. R. Hagan

3981 / 23 - Immune targeting progesterone receptor in hormone receptor positive breast cancer
A. E. Wilson, J. Wei, G. Lei, X.-Y. Yang, C.-X. Liu, M. Gajda, T. Wang, C. Hagan, Z. C. Hartman

SESSION PO.MCB09.05 - Signaling Pathways That Regulate Metabolism 2
9:00 AM - 12:30 PM     
4460 / 14 - Investigating a non-canonical role for SHP2 in pancreatic ductal adenocarcinoma metabolism and response to dietary modifications
R. Walsh, J. L. Jack, A. E. Eades, B. A. Bye, M. T. Ruckert, J. Ambrose, M. N. VanSaun

SESSION LBPO.PR01 - Late-Breaking Research: Prevention, Early Detection, and Interception
1:30 PM - 5:00 PM     
LB381 / 12 - Plasma microbiota as novel biomarkers of early epithelial ovarian cancer detection
D. E. Mahoney, P. Chalise, D. Pei, R. Griffard, T. Home, H. Pathak, S. Umar, A. K. Godwin

SESSION PO.CL01.10 - Predictive Biomarkers 5
1:30 PM - 5:00 PM     
6417 / 29 - Urinary PKM2 in muscle invasive bladder cancer
D. Matye, J. Leak, E. Abbott, B. Woolbright, J. Taylor III

SESSION PO.CTP02.01 - Phase II and Phase III Clinical Trials in Progress
1:30 PM - 5:00 PM     
CT286 / 16 - TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma
S. Thomas, Y. K. Hong, Y. Samhouri, J. Larkin, D. J. Olson, G. K. In, V. Atkinson, P. Lammers, A. J. S. Furness, J. Martin-Liberal, P. Terheyden, A. S. Poklepovic, R. H. Nguyen, I. Peretz, M. Butler, A. Khattak, L. Spain, E. Gaughan, M. Wilson, J. W. Dubay, A. Williams, S. Goff, G. C. Doolittle, J. Chesney, F. Finckenstein, J. Chou, X. Wu, G. Sulur, W. Shi, J. Haanen

SESSION PO.IM02.08 - Tumor-Induced Immune Suppression 2: Intrinsic Factors
1:30 PM - 5:00 PM     
5364 / 15 - Progesterone receptor modulates the antigen processing and presentation machinery decreasing MHC class I expression on tumors
J. Tinoco, L. Werner, E. Chowanec, H. Saunders, S. Xiaopeng, J. Gertz, J. Balko, Z. C. Hartman, C. Hagan

SESSION PO.MCB11.02 - Advances in Cancer Prognostication, Therapeutic Response, and Immune Biology
1:30 PM - 5:00 PM     
5596 / 20 - Exploring BRCA1-Y1853ter and potential therapeutic targets in BRCA1-BRCT mutated cancers
J. Chen

SESSION PO.TB11.06 - Tumor-Immune System Cross-Talk
1:30 PM - 5:00 PM     
5557 / 13 - Stem-like T cells maintain latent anticancer activity and underly therapy resistance
F. Tao, S. McElroy, J. Nemechek, I. Pushel, J. Szarejko, S. Khanal, T. Bradley, D. Myers, J. M. Perry

SESSION MS.EN01.01 - Molecular, Preclinical, and Clinical Endocrinology 3
2:35 PM - 2:50 PM    
Room 5 - Upper Level - Convention Center
6571 - O-GlcNAc sites on progesterone receptor are critical for its ligand independent repression of interferon signaling in breast cancer
H. I. Saunders, S. Holloran, E. Chowanec, J. Tinoco, C. Slawson, C. Hagan

April 10, 2024

SESSION PO.TB11.04 - Chemokines and Cytokines in Cancer
9:00 AM - 12:30 PM     
6803 / 8 - TRIM16 regulates IL-6 secretion in head and neck cancer-associated fibroblasts
T. Ly, B. Pickard, A. Pandey, N. Martinez-Rivera, E. Rosa-Molinar, M. Washburn, W.-X. Ding, S. M. Thomas

SESSION PO.TB11.09 - Immune Cells in the Tumor Microenvironment 2
9:00 AM - 12:30 PM     
6877 / 21 - Progesterone promotes immunosuppression in the murine mammary gland by causing T cell death
A. Heard, L. R. Werner, E. I. Chowanec, H. Saunders, J. Tinoco, Z. C. Hartman, C. R. Hagan

6885 / 29 - Investigating a novel role of DCLK1 isoforms in colitis and colitis associated colon cancer
K. A. Yusuf, B. C. Roy, S. Anant, S. Umar